Inventiv Health (VTIV) 10-Q 13 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 06, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	VTIV
Entity Registrant Name	INVENTIV HEALTH INC
Entity Central Index Key	1,089,473
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		1,000

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
ASSETS
Cash and cash equivalents	$ 80,006	$ 57,059
Restricted cash	1,972	1,717
Accounts receivable, net of allowances for doubtful accounts of $4,764 and $4,143 at September 30, 2015 and December 31, 2014, respectively	308,048	302,847
Unbilled services	240,017	179,036
Prepaid expenses and other current assets	43,639	38,225
Income tax receivable	1,517	1,363
Current deferred tax assets	7,782	7,512
Total current assets	682,981	587,759
Property and equipment, net	129,770	121,859
Goodwill	930,026	931,787
Intangible assets, net	379,786	417,824
Non-current deferred tax assets	3,824	3,944
Deferred financing costs and other assets	79,346	91,262
Total assets	2,205,733	2,154,435
LIABILITIES AND STOCKHOLDER'S DEFICIT
Current portion of capital lease obligations and other financing arrangements	19,390	16,265
Accrued payroll, accounts payable and accrued expenses	318,908	286,613
Income taxes payable	2,800	1,209
Deferred revenue and client advances	229,485	199,130
Total current liabilities	570,583	503,217
Capital lease obligations, net of current portion	36,007	29,324
Long-term debt, net of current portion	2,136,468	2,071,232
Non-current income tax liability	6,752	6,461
Deferred tax liability	84,575	77,232
Other non-current liabilities	70,581	80,756
Total liabilities	$ 2,904,966	$ 2,768,222
Commitments and contingencies (Note 8)
inVentiv Health, Inc. stockholder's deficit:
Common stock, $.01 par value, 1,000 shares authorized, issued and outstanding at September 30, 2015 and December 31, 2014, respectively	$ 1	$ 1
Additional paid-in-capital	572,010	569,863
Accumulated deficit	(1,239,672)	(1,157,668)
Accumulated other comprehensive loss	(32,994)	(27,377)
Total inVentiv Health, Inc. stockholder's deficit	(700,655)	(615,181)
Noncontrolling interest	1,422	1,394
Total stockholder's deficit	(699,233)	(613,787)
Total liabilities and stockholder's deficit	$ 2,205,733	$ 2,154,435

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowances for doubtful accounts	$ 4,764	$ 4,143
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	1,000	1,000
Common stock, shares issued	1,000	1,000
Common stock, shares outstanding	1,000	1,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net revenues	$ 521,410	$ 462,391	$ 1,461,804	$ 1,333,765
Reimbursed out-of-pocket expenses	87,931	62,460	238,331	182,815
Total revenues	609,341	524,851	1,700,135	1,516,580
Operating expenses:
Cost of revenues	336,753	302,389	946,320	869,359
Reimbursable out-of-pocket expenses	87,931	62,460	238,331	182,815
Selling, general and administrative expenses	140,738	140,853	424,375	425,189
Total operating expenses	565,422	505,702	1,609,026	1,477,363
Operating income (loss)	43,919	19,149	91,109	39,217
Loss on extinguishment of debt and refinancing costs		(10,062)		(10,062)
Interest expense	(57,330)	(55,059)	(170,935)	(160,965)
Interest income	36	71	58	293
Other income	11,318		11,318
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	(2,057)	(45,901)	(68,450)	(131,517)
Income tax (provision) benefit	(4,395)	(2,281)	(11,661)	(9,979)
Income (loss) before income (loss) from equity investments	(6,452)	(48,182)	(80,111)	(141,496)
Income (loss) from equity investments	2	(34)	(1,289)	(270)
Income (loss) from continuing operations	(6,450)	(48,216)	(81,400)	(141,766)
Net income (loss) from discontinued operations, net of tax				(8,163)
Net income (loss)	(6,450)	(48,216)	(81,400)	(149,929)
Less: Net (income) loss attributable to the noncontrolling interest	(238)	(9)	(604)	(529)
Net income (loss) attributable to inVentiv Health, Inc.	$ (6,688)	$ (48,225)	$ (82,004)	$ (150,458)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (6,450)	$ (48,216)	$ (81,400)	$ (149,929)
Other comprehensive income (loss):
Foreign currency translation adjustment	(4,390)	(11,274)	(5,617)	(8,584)
Total other comprehensive income (loss)	(4,390)	(11,274)	(5,617)	(8,584)
Total comprehensive income (loss)	(10,840)	(59,490)	(87,017)	(158,513)
Less: Comprehensive (income) loss attributable to the noncontrolling interest	(238)	(9)	(604)	(529)
Comprehensive income (loss) attributable to inVentiv Health, Inc.	$ (11,078)	$ (59,499)	$ (87,621)	$ (159,042)

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholder's Deficit - 9 months ended Sep. 30, 2015 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Non- controlling Interest [Member]
Beginning Balance, Amount at Dec. 31, 2014	$ (613,787)	$ 1	$ 569,863	$ (1,157,668)	$ (27,377)	$ 1,394
Beginning Balance, Shares at Dec. 31, 2014	1,000	1,000
Net income (loss)	$ (81,400)			(82,004)		604
Foreign currency translation adjustment	(5,617)				(5,617)
Stock-based compensation expense	2,147		2,147
Distributions to noncontrolling interest	(576)					(576)
Ending Balance, Amount at Sep. 30, 2015	$ (699,233)	$ 1	$ 572,010	$ (1,239,672)	$ (32,994)	$ 1,422
Ending Balance, Shares at Sep. 30, 2015	1,000	1,000

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income (loss)	$ (81,400)	$ (149,929)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
(Income) loss from discontinued operations, net of tax		8,163
Depreciation	34,838	29,191
Amortization of intangible assets	37,698	50,946
Amortization of deferred financing costs and original issue discount/premium	14,254	14,049
Payment-in-kind interest expense	48,418	7,774
Gain on sale of business	(11,318)
(Gain) loss on sale of vehicles	(210)	(636)
Stock-based compensation expense	2,147	422
Loss on extinguishment of debt		3,537
Deferred taxes	7,069	6,696
Other non-cash adjustments	1,370	32
Changes in assets and liabilities, net
Accounts receivable, net	(12,316)	(13,280)
Unbilled services	(63,057)	(32,505)
Prepaid expenses and other current assets	(3,649)	283
Accrued payroll, accounts payable and accrued expenses	40,216	(16,527)
Net change in income tax receivable and non-current income tax liability	1,837	4,661
Deferred revenue and client advances	40,765	11,014
Other, net	(3,344)	(2,737)
Net cash provided by (used in) continuing operations	53,318	(78,846)
Net cash provided by (used in) discontinued operations		(7,435)
Net cash provided by (used in) operating activities	53,318	(86,281)
Cash flows from investing activities:
Purchases of property and equipment	(28,619)	(24,250)
Proceeds from sale of business	10,691
Proceeds from vehicle sales	6,413	3,785
Proceeds from life insurance distribution	1,800
Return of (disbursements for) investments	224	(2,625)
Other, net	4,983	3,206
Net cash provided by (used in) investing activities	(4,508)	(19,884)
Cash flows from financing activities:
Repayments on capital leases	(20,174)	(12,205)
Borrowings under line of credit	153,000	262,000
Repayment on line of credit	(153,000)	(262,000)
Payment on installment note related to acquisition	(1,750)	(1,500)
Proceeds from issuances of debt		50,000
Payment of debt issuance costs	(324)	(2,319)
Repayment of other financing arrangements	(2,527)	(3,525)
Other, net	(929)	(430)
Net cash provided by (used in) financing activities	(25,704)	30,021
Effects of foreign currency exchange rate changes on cash	(159)	(5,291)
Net increase (decrease) in cash and cash equivalents	22,947	(81,435)
Cash and cash equivalents, beginning of period	57,059	116,227
Cash and cash equivalents, end of period	80,006	34,792
Supplemental disclosure of cash flow information:
Cash paid for interest	104,987	153,749
Cash paid (refunded) for income taxes	2,200	(1,117)
Supplemental disclosure of non-cash activities:
Issuance of Junior Lien Secured Notes for backstop fees		7,000
Vehicles acquired through capital lease agreements, net of transfers	32,302	25,329
Accrued capital expenditures	$ 2,094	$ 3,964

Organization and Business

Organization and Business	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	1. Organization and Business inVentiv Health, Inc. (“inVentiv”, or the “Company”) is a leading provider of outsourced services to the pharmaceutical, biotechnology, medical device and diagnostics, and healthcare industries. The Company is organized into two reportable business segments: Clinical and Commercial. The Company provides a broad range of clinical development and commercialization services that are critical to its clients’ ability to develop and successfully commercialize their products and services. The Company’s portfolio of services meets the varied needs of its clients, who are increasingly outsourcing both their clinical research and development activities, as well as their commercial activities. The Company serves more than 550 client organizations, including all of the 20 largest global pharmaceutical companies. The Company’s service offerings reflect the changing needs of its clients as their products move from early clinical development through the late-stage development and regulatory approval processes and into product launch, and then throughout the post-launch product lifecycle. The Company has established expertise and leadership in providing the services its clients require at each of these stages and seeks to address their outsourced service needs on a comprehensive basis throughout the product life cycle through both standalone and integrated solutions. On August 4, 2010, inVentiv Acquisition, Inc., an indirect, wholly owned subsidiary of inVentiv Group Holdings, Inc. (“Group Holdings” or “Parent”) merged with and into the Company (the “August 2010 Merger”). Group Holdings is controlled by affiliates of Thomas H. Lee Partners (“THL”), a global private investment and advisory firm, as well as certain co-investors, certain members of management and Liberty Lane IH LLC, a private equity investment firm (“Liberty Lane” and together with the private equity funds sponsored by THL, the management investors and the co-investors, the “Investors”). On August 31, 2015, the Company sold inVentiv Patient Access Solutions (“IPAS”), an entity within the Company’s Commercial segment, resulting in a gain on sale of $11.3 million, which was recorded in other income. IPAS had net revenues of $11.9 million and $11.8 million for the nine months ended September 30, 2015 and 2014, respectively. The disposal of IPAS did not result in a strategic shift that has or will have a material impact on the Company’s consolidated financial position or results of operations.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	2. Basis of Presentation The unaudited condensed consolidated financial statements as of and for the three and nine months ended September 30, 2015 are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), include the accounts of inVentiv Health, Inc. and its wholly owned subsidiaries. In addition, the Company consolidates the accounts of its 60% owned subsidiary and reflects the minority interest as a noncontrolling interest classified in equity. The Company has both equity and cost method investments in securities of certain privately held entities. Investments accounted for under the equity method are recorded at the amount of the Company’s investment and adjusted each period for the Company’s share of the investee’s income or loss. During the nine months ended September 30, 2015, the Company recognized a $1.3 million loss on dissolution of a joint venture accounted for under the equity method, which is included in income (loss) from equity investments. Investments accounted for under the cost method are recorded at the historical carrying value. The carrying value of both types of investments is recorded in deferred financing costs and other assets in the consolidated balance sheets and is immaterial. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements as of September 30, 2015 and for the three and nine months ended September 30, 2015 and 2014 are unaudited, but in the opinion of management include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the results for the interim periods. They do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the 2014 audited consolidated financial statements and notes included in our prospectus dated August 5, 2015 on file with the U.S. Securities and Exchange Commission (SEC) relating to our Registration Statement on Form S-4 (File No. 333-197719). The results reported in these condensed consolidated financial statements should not necessarily be viewed as indicative of the results that may be expected for the entire year. The balance sheet at December 31, 2014 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements of the Company have been prepared in conformity with GAAP, which requires management to make estimates and judgments that affect the reported amount of assets, liabilities, revenue, and expenses and disclosure of contingent assets and liabilities in the accompanying financial statements. The significant estimates made by the Company include the estimated forecast that is used in assessing the realizability of the Company’s deferred tax assets and assessing whether the fair value of intangible assets and goodwill exceed the related carrying value. In addition, the Company also makes significant estimates as it relates to revenue recognition, self-insurance reserves, including reserves for employee medical, automobile insurance and worker’s compensation. In the opinion of management, all adjustments considered necessary for a fair presentation have been reflected in these unaudited condensed consolidated financial statements.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	3. Recent Accounting Pronouncements In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2015-03 (“ASU 2015-03”), Interest-Imputation of Interest In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	4. Discontinued Operations In 2012, the Company adopted plans to sell its small non-core medical management business within the Commercial segment, and subsequently abandoned this business in the second quarter of 2014. The following table sets forth the results of the discontinued operations (in thousands): Nine Months September 30, Net revenues $ 3,254 Pre-tax income (loss) from discontinued operations (8,163 ) Income tax (provision) benefit from discontinued operations — Net income (loss) from discontinued operations (8,163 )

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	5. Goodwill The following table sets forth the carrying amount of goodwill as of September 30, 2015 and December 31, 2014 (in thousands): Clinical Commercial Total Net goodwill at December 31, 2014 $ 382,316 $ 549,471 $ 931,787 Foreign currency translation (79 ) (1,682 ) (1,761 ) Net goodwill at September 30, 2015 $ 382,237 $ 547,789 $ 930,026 As of September 30, 2015 and December 31, 2014, the Company had accumulated goodwill impairment losses of $444.3 million.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	6. Intangible Assets The following table sets forth the carrying amount of the Company’s intangible assets as of September 30, 2015 and December 31, 2014 (in thousands): September 30, 2015 December 31, 2014 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Customer relationships $ 404,042 $ (153,228 ) $ 250,814 $ 405,021 $ (128,510 ) $ 276,511 Technology 27,561 (26,515 ) 1,046 27,832 (23,442 ) 4,390 Tradenames subject to amortization 24,206 (20,128 ) 4,078 24,505 (18,513 ) 5,992 Backlog 95,015 (87,434 ) 7,581 95,015 (80,447 ) 14,568 Other 1,020 (555 ) 465 1,020 (465 ) 555 Total finite-lived intangible assets 551,844 (287,860 ) 263,984 553,393 (251,377 ) 302,016 Tradenames not subject to amortization 115,802 — 115,802 115,808 — 115,808 Total intangible assets $ 667,646 $ (287,860 ) $ 379,786 $ 669,201 $ (251,377 ) $ 417,824

Debt

Debt	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt	7. Debt The Company’s indebtedness is summarized as follows (in thousands): September 30, 2015 December 31, 2014 Senior Secured Credit Facilities: Term Loan Facility B3 loans, due 2018 $ 129,645 $ 129,645 Term Loan Facility B4 loans, due 2018 445,694 445,694 Senior Secured Notes, due 2018 625,392 625,489 ABL Facility — — Junior Lien Secured Notes, due 2018 564,291 500,265 Senior Notes, due 2018 371,446 370,139 International Facility — — Capital leases and other financing arrangements 55,397 45,589 Total borrowings 2,191,865 2,116,821 Less: current portion of capital leases and other financing arrangements 19,390 16,265 Total long-term borrowings, net of current portion $ 2,172,475 $ 2,100,556 At September 30, 2015, the Company had $575.3 million outstanding under the Senior Secured Credit Facilities, which consisted of $129.6 million under the B3 term loans and $445.7 million under the B4 term loans. The Company had $625.0 million outstanding under the Senior Secured Notes, excluding $0.4 million of unamortized premium received on issuance, and there were no outstanding borrowings under the ABL Facility (as defined below). The Company also had $564.3 million outstanding under the Junior Lien Secured Notes (as defined below), net of the $5.4 million original issuance discount (“OID”) that is to be accreted over the remaining term, and $371.4 million outstanding under the Senior Notes, net of the $4.9 million OID that is to be accreted over the remaining term. In addition, the Company had capitalized leases and other financing arrangements of $55.4 million outstanding as of September 30, 2015. On July 1, 2015 one of the Company’s indirect subsidiaries in the United Kingdom entered into an asset-based lending facility (“International Facility”) for up to $20.0 million. The new facility includes a guaranty from inVentiv Health, Inc.’s indirect subsidiary in Switzerland. The borrower and guarantor for the new facility are not directly held by inVentiv Health, Inc. or any guarantor to its lending facilities in the U.S. This new facility will be used to enhance international cash management. At September 30, 2015, the Company had no outstanding borrowings under the International Facility. On August 15, 2014, the Company consummated an exchange offer (the “Junior Lien Notes Exchange Offer”) with holders of its 10% Senior Notes due 2018 in which the Company issued $475.0 million aggregate principal amount of new 10%/12% Junior Lien Secured Notes due 2018 (the “Junior Lien Secured Notes”) in exchange for a like amount of the Company’s 10% Senior Notes due 2018. The Junior Lien Secured Notes permit up to six semi-annual interest payments to be settled through the issuance of additional Junior Lien Secured Notes. The interest rate with respect to the Junior Lien Secured Notes is a cash rate of 10% per annum and a payment-in-kind (“PIK”) rate of 12% per annum (“PIK Interest”). The Company paid interest on the Junior Lien Secured Notes for the periods commencing August 15, 2014 and February 15, 2015 in PIK Interest and elected to pay interest for the period commencing August 15, 2015 in PIK Interest. As of September 30, 2015, the Company accrued 12% interest on the Junior Lien Secured Notes related to the August 15, 2015 PIK Interest election, which is included in other non-current liabilities, as such interest is required to be settled through the issuance of additional Junior Lien Secured Notes on the interest payment date. On August 12, 2014, in connection with the Junior Lien Notes Exchange Offer, affiliates of Thomas H. Lee Partners, L.P. and certain co-investors purchased $25.0 million of Junior Lien Secured Notes and $26.3 million of the Company’s 10% Senior Notes due 2018 for a total consideration of $50.0 million (the “New Money Investment”). The $26.3 million of 10% Senior Notes due 2018 were issued at a 5% discount to par value resulting in a $1.3 million discount that will be accreted over the related term using the effective interest method. Additionally, on August 15, 2014 the Company issued an additional $7.0 million of Junior Lien Secured Notes (the “Backstop Consideration”) to a group of holders of the Company’s 10% Senior Notes due 2018 as consideration for such holders’ agreement to tender the 10% Senior Notes due 2018 held by them into the Junior Lien Notes Exchange Offer. In connection with the Junior Lien Notes Exchange Offer, the Company’s term loan facility and asset-backed revolving facility were amended on July 28, 2014 (the “Credit Agreement Amendments”) to permit the Junior Lien Notes Exchange Offer, the New Money Investment and the issuance of the Backstop Consideration and to extend the maturities of certain outstanding term loans from 2016 to 2018. The margin on the term loans increased by 0.25% when compared to the interest rates on the prior term loans. There was no net change in the outstanding principal balance of the term loans as a result of the modified terms. In connection with these transactions, the Company recognized a loss on extinguishment of debt and refinancing costs of approximately $10.1 million in the third quarter of 2014. The extinguishment of debt relates to the write-off of unamortized deferred borrowing costs associated with non-participating lenders and the refinancing costs represent the third party fees associated with the transactions that were deemed a modification as the terms of the new debt instruments were not substantially different than the prior instruments. On August 16, 2013, the Company, Citibank, N.A. and certain financial institutions entered into a credit agreement for an asset-based revolving credit facility of up to $150.0 million (the “ABL Facility”), subject to borrowing base availability, which matures on August 16, 2018. Up to $35.0 million of the ABL Facility is available for the issuance of letters of credit. Amounts borrowed under the ABL Facility are subject to interest at a rate per annum equal to an applicable margin plus, at the Company’s option, either (a) a base rate determined by reference to the highest of (i) the Federal Funds Rate plus .5%, (ii) the prime rate of Citibank, N.A., or (iii) the one month US Dollar LIBOR rate plus 1.0% or (b) the US Dollar LIBOR rate based on the term of the borrowing. The applicable margin percentage for revolving loans is a percentage per annum and ranges from 1.0% to 1.5% for Base Rate loans or 2.0% to 2.5% for the Eurodollar rate loans. The applicable margin percentages with respect to borrowings under the ABL Facility is subject to adjustments based on historical excess availability as defined in the credit agreement for the ABL Facility. As of September 30, 2015, the Company had no outstanding borrowings under its ABL facility and the interest rate applicable to any outstanding borrowings was 4.25% at September 30, 2015. The Company is required to pay an unused line fee on the committed but unutilized balance of the ABL Facility at a rate per annum of 0.25% or 0.375%, depending on utilization. The ABL Facility contains customary covenants and restrictions on the Company and its subsidiaries’ activities, including but not limited to, limitations on the incurrence of additional indebtedness, use of cash in certain circumstances, dividends, repurchase of capital stock, investments, loans, asset sales, distributions and acquisitions. The ABL Facility requires the Company to maintain a fixed-charge coverage ratio of at least 1.0 to 1.0 and requires certain cash management restrictions, in each case, if available borrowing capacity is less than the greater of 10% of the maximum amount that can be borrowed under the ABL Facility, based on the borrowing base at such time, and $12.0 million. The requirement to maintain a minimum fixed-charge coverage ratio was not in effect given the Company’s available borrowing capacity as of September 30, 2015. All obligations under the ABL Facility are secured by the Company’s domestic subsidiaries and secured by a first priority lien on current assets of the Company and its domestic subsidiaries and a second priority lien on all other assets of the Company and its domestic subsidiaries. The credit agreement also contains events of default for breach of principal or interest payments, breach of certain representations and warranties, breach of covenants and other customary events of default. The available borrowing capacity varies monthly according to the levels of the Company’s eligible accounts receivable and unbilled receivables. As of September 30, 2015, the Company had no outstanding borrowings under the ABL Facility, approximately $18.4 million in letters of credit outstanding against the ABL Facility and would have been able to borrow up to an additional $131.6 million. Cash Pooling The Company and certain of its international subsidiaries participate in a notional cash pooling arrangement (“Cash Pool”) to help manage global liquidity requirements. The parties to the arrangement combine their cash balances in pooling accounts with the ability to set-off overdrafts to the bank against positive cash balances. Each subsidiary receives interest on the cash balances or pays interest on amounts owed. At September 30, 2015, the Company’s net cash position in the pool of $8.4 million, defined as the gross cash position in the pool of $100.3 million less borrowings of $91.9 million, is reflected as cash and cash equivalents in the condensed consolidated balance sheet. Fair Value of Long-Term Debt The carrying amounts and the estimated fair values of long-term debt as of September 30, 2015 and December 31, 2014 are as follows (in thousands): September 30, 2015 December 31, 2014 Carrying value Estimated fair value Carrying value Estimated fair value Term Loan Facility $ 575,339 $ 572,463 $ 575,339 $ 571,024 Senior Secured Notes 625,392 644,154 625,489 637,217 Junior Lien Secured Notes 564,291 560,764 500,265 463,370 Senior Notes 371,446 358,910 370,139 322,569 The fair value of long-term debt instruments is measured based on market values for debt issues with similar characteristics, such as maturities, credit ratings, collateral and interest rates available on the measurement dates for debt with similar terms (level 2 within the fair value hierarchy). The Company believes the carrying values for capital leases and other financing arrangements approximate their fair values.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies	8. Contingencies On October 31, 2013, Cel-Sci Corporation (Cel-Sci) (“Claimant”) made a demand for arbitration under a Master Services Agreement (the “MSA”), dated as of April 6, 2010 between Claimant and two of our subsidiaries, inVentiv Health Clinical, LLC (formerly known as PharmaNet, LLC) and PharmaNet GmbH (currently known as inVentiv Health Switzerland GmbH and formerly known as PharmaNet AG) (collectively, “PharmaNet”). Under the MSA and related project agreement, which were terminated by Claimant in April 2013, Claimant engaged PharmaNet in connection with a Phase III Clinical Trial of its investigational drug. The arbitration claim alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud on the part of PharmaNet, and seeks damages of at least $50 million. In December 2013, inVentiv Health Clinical, LLC filed a counterclaim against Claimant that alleges breach of contract and seeks at least $2 million in damages. The matter proceeded to the discovery phase. In January 2015, inVentiv Health Clinical, LLC filed additional counterclaims against Claimant that allege (i) breach of contract, (ii) opportunistic breach, restitution and unjust enrichment, and (iii) defamation, and seeks at least $2 million in damages and $20 million in other equitable remedies. A hearing is set for the first half of 2016. No assessment can be made at this time as to the likely outcome of this matter. Other Matters The Company is subject to lawsuits, investigations and claims arising out of the conduct of its business, including those related to commercial transactions, contracts, government regulation and employment matters. Certain claims, suits and complaints have been filed or are pending against the Company. In the opinion of management, taking into account the advice of legal counsel, no matters outstanding as of September 30, 2015 arising out of the conduct of the Company’s business are likely to have a material effect to the Company on an individual or aggregate basis.

Concentration of Credit Risk

Concentration of Credit Risk	9 Months Ended
	Sep. 30, 2015
Risks and Uncertainties [Abstract]
Concentration of Credit Risk	9. Concentration of Credit Risk The Company’s receivables are concentrated with major pharmaceutical companies. Credit risk is managed through the monitoring of exposures with the Company’s customers. The Company does not require collateral or other security to support customer receivables. For the three months ended September 30, 2015, one customer accounted for approximately 11% of the Company’s consolidated net revenues. No customer accounted for 10% or more of the Company’s consolidated net revenues for the nine months ended September 30, 2015. For the three and nine months ended September 30, 2014, one customer accounted for approximately 11% of the Company’s consolidated net revenues. As of September 30, 2015, no customer accounted for 10% or more of the Company’s consolidated accounts receivable.

Common Stock and Stock Incentiv

Common Stock and Stock Incentive Plans	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock and Stock Incentive Plans	10. Common Stock and Stock Incentive Plans On July 2, 2015 the Company’s Board of Directors approved the grant of new option awards to eligible employees in exchange for certain outstanding restricted stock units granted under the Group Holdings’ equity incentive plan, on a one-for-one basis. Thirty-five percent of the options in the new award vest upon the passage of time and completion of a service requirement and sixty-five percent vests based upon achievement of certain specified performance targets and completion of a service requirement. Approximately 156,106 of the outstanding restricted stock units were exchanged in the program. The Company recognizes the fair value of the new option awards in compensation expense over the service period to the extent that vesting of the awards is considered probable.

Termination Benefits and Other

Termination Benefits and Other Cost Reduction Actions	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Termination Benefits and Other Cost Reduction Actions	11. Termination Benefits and Other Cost Reduction Actions The Company undertook certain cost containment measures in an effort to better align operating costs with market and business conditions. Expenses related to these actions, which include real estate consolidations, elimination of redundant functions and employees, were summarized below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Employee severance and related costs $ 4,117 $ 1,976 $ 10,241 $ 8,947 Facilities-related costs 601 123 932 3,797 Total $ 4,718 $ 2,099 $ 11,173 $ 12,744 For the three and nine months ended September 30, 2015 restructuring costs of $1.2 million and $4.2 million have been included in cost of revenues and $3.5 million and $7.0 million have been included in selling, general and administrative expenses (“SG&A expenses”), respectively. For the three and nine months ended September 30, 2014 restructuring costs of $1.2 million and $2.5 million have been included in cost of revenues and $0.9 million and $10.2 million have been included in SG&A expenses, respectively. The following table summarizes the Company’s restructuring reserve as of September 30, 2015 and December 31, 2014 (in thousands): Balance at December 31, 2014 Net Costs Cash Payments Balance at September 30, 2015 Employee severance and related costs $ 5,145 $ 10,241 $ (10,291 ) $ 5,095 Facilities-related charges 7,098 932 (4,846 ) 3,184 Total $ 12,243 $ 11,173 $ (15,137 ) $ 8,279 The Company expects that severance payments accrued at September 30, 2015 will be paid within the next twelve months. Certain facility costs will be paid over the remaining lease term of the exited facilities through 2019. The net costs in the table above exclude non-cash charges of approximately $0.5 million for the nine months ended September 30, 2015 related to abandoned assets at certain facilities.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes The Company accounts for income taxes at each interim period using its estimated annual effective tax rate. Discrete items and changes in the estimate of the annual effective tax rate are recorded in the period they occur. The consolidated effective tax rate was approximately (213.7%) and (5.0%) for the three months ended September 30, 2015 and 2014, respectively, and (17.0%) and (7.6%) for the nine months ended September 30, 2015 and 2014, respectively. The income tax provision for the three and nine months ended September 30, 2015 and 2014 reflects that the Company (i) continues to record a full valuation allowance for its domestic and certain foreign tax jurisdictions, (ii) records a tax provision for certain foreign and state jurisdictions which are generating earnings, and (iii) incurs taxable temporary differences related to the amortization of indefinite-lived intangible assets and goodwill. The Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable value if, based on the weight of all available evidence, it is not more likely than not that a portion or all of the deferred tax assets will be realized. The Company does not expect to record significant tax benefits on future domestic net operating losses until circumstances justify the recognition of such benefits. As a result of the domestic valuation allowance, taxable temporary differences from the amortization of goodwill and indefinite-lived intangible assets are expected to result in $7.7 million of income tax expense for 2015, and are reflected in the Company’s estimated domestic annual effective tax rate. Goodwill and indefinite-lived intangible assets are amortized for income tax purposes, but not for financial statement reporting purposes. This difference results in net deferred income tax expense since the taxable temporary difference cannot be scheduled to reverse during the loss carryforward period. The Company will record tax expense related to the amortization of its tax deductible goodwill and indefinite-lived intangible assets during those future periods for which it maintains domestic valuation allowances, or until its estimated unamortized balance of $134.7 million at December 31, 2015 is fully amortized for tax purposes.

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Parties	13. Related Parties Management Arrangements Upon completion of the August 2010 Merger, the Company entered into a management agreement (“THL Management Agreement”) with THL Managers VI, LLC (“THL Managers”), in which THL Managers agreed to provide management services to the Company. Pursuant to the THL Management Agreement, THL Managers will receive an aggregate annual management fee in an amount per year equal to the greater of (a) $2.5 million or (b) 1.5% of EBITDA, as defined. In addition, the Company will reimburse out-of-pocket expenses incurred by THL Managers. The Company recognized $0.7 million in management fees for each of the three months ended September 30, 2015 and 2014, and $2.1 million for each of the nine months ended September 30, 2015 and 2014. Upon completion of the August 2010 Merger, the Company entered into a management agreement with Liberty Lane, in which Liberty Lane agreed to provide management services to the Company. Mr. Meister, the Company’s former Chief Executive Officer, is affiliated with Liberty Lane. Pursuant to the agreement, Liberty Lane or its affiliates received an aggregate annual management fee in an amount per year equal to $1.0 million. On December 5, 2012, the agreement was amended to lower the per year management fee to $0.8 million beginning January 1, 2013. The agreement was terminated in the second quarter of 2015 with an effective date of September 24, 2014 to reflect Mr. Meister’s resignation as Chief Executive Officer. The Company incurred management fees of $0.2 million and $0.6 million for the three and nine months ended September 30, 2014. Commercial Transactions There were four entities for the three and nine months ended September 30, 2015 and 2014 in which THL or its affiliates held a 10% or greater interest that provided services exceeding $120,000 in value to the Company. The services included facilities management, audio conferencing and information technology services. The fees for these services were $1.2 million and $2.1 million for the three months ended September 30, 2015 and 2014, respectively, and $3.9 million and $4.4 million for the nine months ended September 30, 2015 and 2014, respectively. One of the Company’s directors, Blane Walter, acquired a 10% or greater interest in and became a director of an entity in 2013 which provided relationship enterprise technology solutions to the Company exceeding $120,000 in value over the previous twelve month period. The services were provided for fees of $0.2 million for the three months ended September 30, 2014, and $1.8 million and $1.7 million for the nine months ended September 30, 2015 and 2014, respectively. Debt Instruments Affiliates of Thomas H. Lee Partners, L.P., Liberty Lane and Blane Walter purchased $25.0 million of Junior Lien Secured Notes and $26.3 million of the Company’s 10% Senior Notes due 2018 for a total consideration of $50.0 million as described in Note 7.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	14. Fair Value Measurements The Company’s financial instruments include cash and cash equivalents, accounts receivables, unbilled services, accounts payable, short-term borrowings and current portion of capital leases and other financing arrangements as well as deferred revenues and client advances. Due to the short-term nature of such instruments, the Company believes their carrying values approximate fair value. Please refer to Note 7 for discussion of the Company’s debt instruments. The Company’s contingent consideration obligations are the only instruments measured at fair value on a recurring basis. The contingent consideration is determined based upon significant inputs not observable in the market, including the fair value and the Company’s best estimate as to the probable timing and amount of settlement. As of September 30, 2015, the contingent consideration obligations had an aggregate fair value of $1.4 million, which is included in accrued expenses and other non-current liabilities, resulting in a $0.4 million adjustment to decrease earnings for the nine months ended September 30, 2015, respectively.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Information	15. Segment Information The Company is managed through two reportable segments, Clinical and Commercial. Each reportable business segment is comprised of multiple divisions and business units that, through their combination, create a fully integrated biopharmaceutical outsourced services provider. Clinical, which primarily serves pharmaceutical, biotechnology, diagnostic and medical device clients engaged in research and development, provides a continuum of services spanning phases I-IV of clinical development. Commercial, provides commercialization, patient outcomes and consulting services to the pharmaceutical, biotechnology and healthcare industries. In the fourth quarter of 2014, the Company realigned its segment reporting structure to reflect changes in its management structure. As a result of these changes, the Commercial segment includes the results of the consulting business, previously reported separately as the Consulting segment. Additionally, during 2014 certain business units previously reported under the Commercial segment were operationally moved into and are now reported under the Clinical segment, certain segment leadership costs previously included in Corporate and other were allocated to the Commercial segment and certain information technology costs previously allocated to the segments will remain in Corporate and other. As a result, previously reported segment information has been restated to conform to management’s current operating structure. Management measures and evaluates the Company’s operating segments based on segment net revenue and adjusted operating income. The results of these reportable business segments are regularly reviewed by the Company’s chief operating decision maker, the Chief Executive Officer. Certain amounts that management considers to be non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such charges. These items include depreciation and amortization; certain foreign currency impacts; net charges associated with acquisitions; certain legal charges, net of insurance recoveries; certain asset impairment charges; stock-based compensation; as well as corporate and other unallocated expenses. The corporate and other unallocated expenses primarily consist of expenses for corporate overhead functions such as finance, human resources, information technology, facilities and legal; restructuring and related charges; and certain expenses incurred in connection with the management agreements with affiliates of certain shareholders of the Parent. Although these amounts are excluded from segment operating income, as applicable, they are included in reported consolidated operating loss and in the reconciliations presented below. The Company has not presented segment assets since management does not evaluate the Company’s operating segments using this information. In the third quarter of 2015, certain costs incurred in connection with an agreement to provide commercialization services to a pharmaceutical customer for launch of certain specified products in return for a royalty on the net sales which were previously reported in the Commercial segment were moved to Corporate. The Company moved these costs to Corporate to better reflect the role of the Corporate executive team in managing this client relationship. As a result, previously reported segment information has been restated to conform to this presentation. Selected information for each reportable segment is as follows (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Net Revenues Clinical $ 244,570 $ 215,695 $ 697,816 $ 648,669 Commercial 279,147 248,242 773,155 689,989 Intersegment revenues (2,307 ) (1,546 ) (9,167 ) (4,893 ) Consolidated net revenues $ 521,410 $ 462,391 $ 1,461,804 $ 1,333,765 Adjusted Segment Operating Income (Loss) Clinical $ 38,713 $ 25,140 $ 92,831 $ 70,002 Commercial 46,312 35,146 121,177 87,313 Corporate and other (10,908 ) (10,050 ) (29,842 ) (20,372 ) Reportable segments adjusted operating income (loss) 74,117 50,236 184,166 136,943 Depreciation and amortization (23,625 ) (26,555 ) (72,536 ) (80,137 ) Stock-based compensation (1,632 ) 22 (2,147 ) (422 ) Other unallocated charges (4,941 ) (4,554 ) (18,374 ) (17,167 ) Operating income (loss) $ 43,919 $ 19,149 $ 91,109 $ 39,217 Loss on extinguishment of debt and refinancing costs — (10,062 ) — (10,062 ) Interest income (expense), net (57,294 ) (54,988 ) (170,877 ) (160,672 ) Other income 11,318 — 11,318 — Income (loss) before income tax (provision) benefit and income (loss) from equity investments. $ (2,057 ) $ (45,901 ) $ (68,450 ) $ (131,517 )

Guarantor Financial Information

Guarantor Financial Information	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Guarantor Financial Information	16. Guarantor Financial Information Borrowings under each of our Senior Secured Credit Facilities, ABL Facility, Senior Secured Notes, Junior Lien Secured Notes and Senior Notes are guaranteed by certain of the Company’s domestic wholly-owned subsidiaries. The guarantees are full and unconditional and joint and several. The Company’s Senior Secured Credit Facility, ABL Facility, Senior Secured Notes, Junior Lien Secured Notes and Senior Notes are not guaranteed by certain of the Company’s subsidiaries, including all of its non-U.S. subsidiaries or non-wholly owned subsidiaries. The following supplemental financial information sets forth, on a condensed consolidating basis, balance sheet information, results of operations, comprehensive loss and cash flow information for inVentiv Health, Inc., the Guarantor Subsidiaries and other subsidiaries (the “Non-Guarantor Subsidiaries”). The supplemental financial information reflects the investments of inVentiv Health, Inc.’s investment in the Guarantor Subsidiaries and Non-Guarantor Subsidiaries using the equity method of accounting. Subsequent to the issuance of the June 30, 2015 consolidated financial statements, management determined that within the condensed consolidating statement of cash flows, certain intercompany transfers historically presented on a gross basis within operating, investing and financing activities represent centralized treasury activities that are more appropriately presented on a net basis within investing and financing activities between the respective parent, guarantor, and non guarantor entities. Additionally, the Company has recorded in Guarantor Subsidiaries approximately $575.3 million of long term debt as well as adjustments for debt-related accounts previously shown in the parent column, representing the co-obligator subsidiaries share of the Company’s outstanding term loan debt. The aforementioned items have been corrected in the condensed consolidating statements as of December 31, 2014 and for the three and nine months ended September 30, 2014. The corrections had no impact on the Company’s consolidated financial position, results of operations or cash flows. CONDENSED CONSOLIDATING BALANCE SHEET INFORMATION At September 30, 2015 (in thousands, except share and per share amounts) inVentiv Guarantor Non- Guarantor Eliminations Total ASSETS Current assets: Cash and cash equivalents $ 65,509 $ — $ 119,106 $ (104,609 ) $ 80,006 Restricted cash 553 — 1,419 — 1,972 Accounts receivable, net of allowances for doubtful accounts — 252,143 55,905 — 308,048 Unbilled services — 196,521 43,496 — 240,017 Intercompany receivables 488,420 749,921 93,234 (1,331,575 ) — Prepaid expenses and other current assets 8,541 15,111 19,987 — 43,639 Income tax receivable 85 502 930 — 1,517 Current deferred tax assets 259 12,198 1,586 (6,261 ) 7,782 Total current assets 563,367 1,226,396 335,663 (1,442,445 ) 682,981 Property and equipment, net 23,170 90,853 15,747 — 129,770 Goodwill — 889,281 40,745 — 930,026 Intangible assets, net — 373,101 6,685 — 379,786 Non-current deferred tax assets — — 3,824 — 3,824 Deferred financing costs and other assets 51,690 12,624 15,032 — 79,346 Non-current intercompany receivables 403,917 29,625 136 (433,678 ) — Investment in consolidated subsidiaries 728,742 92,458 — (821,200 ) — Total assets $ 1,770,886 $ 2,714,338 $ 417,832 $ (2,697,323 ) $ 2,205,733 LIABILITIES AND STOCKHOLDER’S DEFICIT Current liabilities: Current portion of capital lease obligations and other financing arrangements $ — $ 19,266 $ 92,005 $ (91,881 ) $ 19,390 Accrued payroll, accounts payable and accrued expenses 80,456 190,314 60,866 (12,728 ) 318,908 Intercompany payables 809,634 501,879 20,062 (1,331,575 ) — Income taxes payable — 75 2,725 — 2,800 Deferred revenue and client advances — 174,532 54,953 — 229,485 Total current liabilities 890,090 886,066 230,611 (1,436,184 ) 570,583 Capital lease obligations, net of current portion — 35,971 36 — 36,007 Long-term debt, net of current portion 1,560,129 576,339 — — 2,136,468 Non-current income tax liability — 5,543 1,209 — 6,752 Deferred tax liability 333 86,659 3,844 (6,261 ) 84,575 Other non-current liabilities 20,989 31,362 18,230 — 70,581 Non-current intercompany liabilities — 404,050 29,628 (433,678 ) — Total liabilities 2,471,541 2,025,990 283,558 (1,876,123 ) 2,904,966 Total inVentiv Health, Inc. stockholder’s deficit (700,655 ) 688,348 132,852 (821,200 ) (700,655 ) Noncontrolling interest — — 1,422 — 1,422 Total stockholder’s deficit (700,655 ) 688,348 134,274 (821,200 ) (699,233 ) Total liabilities and stockholder’s deficit $ 1,770,886 $ 2,714,338 $ 417,832 $ (2,697,323 ) $ 2,205,733 CONDENSED CONSOLIDATING BALANCE SHEET INFORMATION At December 31, 2014 (in thousands, except share and per share amounts) inVentiv Guarantor Non- Guarantor Eliminations Total ASSETS Current assets: Cash and cash equivalents $ 19,643 $ 3,439 $ 86,014 $ (52,037 ) $ 57,059 Restricted cash 569 — 1,148 — 1,717 Accounts receivable, net of allowances for doubtful accounts — 236,884 65,963 — 302,847 Unbilled services — 138,100 40,936 — 179,036 Intercompany receivables 375,025 557,758 64,778 (997,561 ) — Prepaid expenses and other current assets 5,301 12,181 20,743 — 38,225 Income tax receivable — 310 1,053 — 1,363 Current deferred tax assets 259 12,198 1,316 (6,261 ) 7,512 Total current assets 400,797 960,870 281,951 (1,055,859 ) 587,759 Property and equipment, net 21,665 82,857 17,337 — 121,859 Goodwill — 889,281 42,506 — 931,787 Intangible assets, net — 410,059 7,765 — 417,824 Non-current deferred tax assets — — 3,944 — 3,944 Deferred financing costs and other assets 64,484 14,331 12,447 — 91,262 Non-current intercompany receivables 368,325 38,847 132 (407,304 ) — Investment in consolidated subsidiaries 700,383 86,242 — (786,625 ) — Total assets $ 1,555,654 $ 2,482,487 $ 366,082 $ (2,249,788 ) $ 2,154,435 LIABILITIES AND STOCKHOLDER’S DEFICIT Current liabilities: Current portion of capital lease obligations and other financing arrangements $ 4,006 $ 14,025 $ 50,271 $ (52,037 ) $ 16,265 Accrued payroll, accounts payable and accrued expenses 62,179 162,937 61,497 — 286,613 Intercompany payables 562,297 404,413 30,851 (997,561 ) — Income taxes payable 222 — 987 — 1,209 Deferred revenue and client advances — 150,709 48,421 — 199,130 Total current liabilities 628,704 732,084 192,027 (1,049,598 ) 503,217 Capital lease obligations, net of current portion — 29,126 198 — 29,324 Long-term debt, net of current portion 1,494,893 576,339 — — 2,071,232 Non-current income tax liability — 5,360 1,101 — 6,461 Deferred tax liability 333 80,860 2,300 (6,261 ) 77,232 Other non-current liabilities 37,441 25,175 18,140 — 80,756 Non-current intercompany liabilities 9,464 368,457 29,383 (407,304 ) — Total liabilities 2,170,835 1,817,401 243,149 (1,463,163 ) 2,768,222 Total inVentiv Health, Inc. stockholder’s deficit (615,181 ) 665,086 121,539 (786,625 ) (615,181 ) Noncontrolling interest — — 1,394 — 1,394 Total stockholder’s deficit (615,181 ) 665,086 122,933 (786,625 ) (613,787 ) Total liabilities and stockholder’s deficit $ 1,555,654 $ 2,482,487 $ 366,082 $ (2,249,788 ) $ 2,154,435 CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended September 30, 2015 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net revenues $ — $ 408,448 $ 119,469 $ (6,507 ) $ 521,410 Reimbursed out-of-pocket expenses — 77,745 10,290 (104 ) 87,931 Total revenues — 486,193 129,759 (6,611 ) 609,341 Operating expenses: Cost of revenues — 271,754 70,895 (5,896 ) 336,753 Reimbursable out-of-pocket expenses — 77,745 10,290 (104 ) 87,931 Selling, general and administrative expenses 22,866 88,264 30,219 (611 ) 140,738 Allocation of intercompany costs (9,854 ) 7,886 1,968 — — Total operating expenses 13,012 445,649 113,372 (6,611 ) 565,422 Operating income (loss) (13,012 ) 40,544 16,387 — 43,919 Interest income (expense), net (44,994 ) (12,445 ) 145 — (57,294 ) Other income 11,318 — — — 11,318 Intercompany interest income (expense) 12,342 (12,025 ) (317 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (34,346 ) 16,074 16,215 — (2,057 ) Income tax (provision) benefit — (1,488 ) (2,907 ) — (4,395 ) Income (loss) before income (loss) from equity investments (34,346 ) 14,586 13,308 — (6,452 ) Income (loss) from equity investments 27,658 10,728 — (38,384 ) 2 Net income (loss) (6,688 ) 25,314 13,308 (38,384 ) (6,450 ) Less: Net (income) loss attributable to the noncontrolling interest — — (238 ) — (238 ) Net income (loss) attributable to inVentiv Health, Inc. $ (6,688 ) $ 25,314 $ 13,070 $ (38,384 ) $ (6,688 ) CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended September 30, 2014 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net revenues $ — $ 346,452 $ 122,277 $ (6,338 ) $ 462,391 Reimbursed out-of-pocket expenses — 49,283 13,207 (30 ) 62,460 Total revenues — 395,735 135,484 (6,368 ) 524,851 Operating expenses: Cost of revenues — 228,411 79,907 (5,929 ) 302,389 Reimbursable out-of-pocket expenses — 49,283 13,207 (30 ) 62,460 Selling, general and administrative expenses 13,892 89,727 37,643 (409 ) 140,853 Allocation of intercompany costs (11,743 ) 8,960 2,783 — — Total operating expenses 2,149 376,381 133,540 (6,368 ) 505,702 Operating income (loss) (2,149 ) 19,354 1,944 — 19,149 Loss on extinguishment of debt and refinancing costs (3,570 ) (6,492 ) — — (10,062 ) Interest income (expense), net (42,273 ) (12,759 ) 44 — (54,988 ) Intercompany interest income (expense) 10,767 (10,157 ) (610 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (37,225 ) (10,054 ) 1,378 — (45,901 ) Income tax (provision) benefit — (893 ) (1,388 ) — (2,281 ) Income (loss) before income (loss) from equity investments (37,225 ) (10,947 ) (10 ) — (48,182 ) Income (loss) from equity investments (11,000 ) (286 ) — 11,252 (34 ) Net income (loss) (48,225 ) (11,233 ) (10 ) 11,252 (48,216 ) Less: Net (income) loss attributable to the noncontrolling interest — — (9 ) — (9 ) Net income (loss) attributable to inVentiv Health, Inc. $ (48,225 ) $ (11,233 ) $ (19 ) $ 11,252 $ (48,225 ) CONSOLIDATING STATEMENT OF OPERATIONS Nine Months Ended September 30, 2015 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net revenues $ — $ 1,138,337 $ 342,147 $ (18,680 ) $ 1,461,804 Reimbursed out-of-pocket expenses — 205,811 32,762 (242 ) 238,331 Total revenues — 1,344,148 374,909 (18,922 ) 1,700,135 Operating expenses: Cost of revenues — 750,784 212,579 (17,043 ) 946,320 Reimbursable out-of-pocket expenses — 205,811 32,762 (242 ) 238,331 Selling, general and administrative expenses 59,444 266,007 100,561 (1,637 ) 424,375 Allocation of intercompany costs (29,654 ) 23,765 5,889 — — Total operating expenses 29,790 1,246,367 351,791 (18,922 ) 1,609,026 Operating income (loss) (29,790 ) 97,781 23,118 — 91,109 Interest income (expense), net (134,399 ) (36,892 ) 414 — (170,877 ) Other income 11,318 — — — 11,318 Intercompany interest income (expense) 35,265 (34,551 ) (714 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (117,606 ) 26,338 22,818 — (68,450 ) Income tax (provision) benefit — (6,113 ) (5,548 ) — (11,661 ) Income (loss) before income (loss) from equity investments (117,606 ) 20,225 17,270 — (80,111 ) Income (loss) from equity investments 35,602 11,382 — (48,273 ) (1,289 ) Net income (loss) (82,004 ) 31,607 17,270 (48,273 ) (81,400 ) Less: Net (income) loss attributable to the noncontrolling interest — — (604 ) — (604 ) Net income (loss) attributable to inVentiv Health, Inc. $ (82,004 ) $ 31,607 $ 16,666 $ (48,273 ) $ (82,004 ) CONSOLIDATING STATEMENT OF OPERATIONS Nine Months Ended September 30, 2014 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net revenues $ — $ 989,307 $ 376,158 $ (31,700 ) $ 1,333,765 Reimbursed out-of-pocket expenses — 143,347 39,739 (271 ) 182,815 Total revenues — 1,132,654 415,897 (31,971 ) 1,516,580 Operating expenses: Cost of revenues — 656,655 242,731 (30,027 ) 869,359 Reimbursable out-of-pocket expenses — 143,347 39,739 (271 ) 182,815 Selling, general and administrative expenses 31,693 282,328 112,841 (1,673 ) 425,189 Allocation of intercompany costs (35,229 ) 26,853 8,376 — — Total operating expenses (3,536 ) 1,109,183 403,687 (31,971 ) 1,477,363 Operating income (loss) 3,536 23,471 12,210 — 39,217 Loss on extinguishment of debt and refinancing costs (3,570 ) (6,492 ) — — (10,062 ) Interest income (expense), net (122,959 ) (38,000 ) 287 — (160,672 ) Intercompany interest income (expense) 31,265 (29,324 ) (1,941 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (91,728 ) (50,345 ) 10,556 — (131,517 ) Income tax (provision) benefit (127 ) (6,584 ) (3,268 ) — (9,979 ) Income (loss) before income (loss) from equity investments (91,855 ) (56,929 ) 7,288 — (141,496 ) Income (loss) from equity investments (58,603 ) 3,617 — 54,716 (270 ) Income (loss) from continuing operations (150,458 ) (53,312 ) 7,288 54,716 (141,766 ) Net income (loss) from discontinued operations, net of tax — (8,163 ) — — (8,163 ) Net income (loss) (150,458 ) (61,475 ) 7,288 54,716 (149,929 ) Less: Net (income) loss attributable to the noncontrolling interest — — (529 ) — (529 ) Net income (loss) attributable to inVentiv Health, Inc. $ (150,458 ) $ (61,475 ) $ 6,759 $ 54,716 $ (150,458 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS For the Three Months Ended September 30, 2015 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net income (loss) $ (6,688 ) $ 25,314 $ 13,308 $ (38,384 ) $ (6,450 ) Other comprehensive income (loss): Foreign currency translation adjustment (4,390 ) (5,260 ) (3,272 ) 8,532 (4,390 ) Total other comprehensive income (loss) (4,390 ) (5,260 ) (3,272 ) 8,532 (4,390 ) Total comprehensive income (loss) (11,078 ) 20,054 10,036 (29,852 ) (10,840 ) Less: Net (income) loss attributable to the noncontrolling interest — — (238 ) — (238 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (11,078 ) $ 20,054 $ 9,798 $ (29,852 ) $ (11,078 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS For the Three Months Ended September 30, 2014 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net income (loss) $ (48,225 ) $ (11,233 ) $ (10 ) $ 11,252 $ (48,216 ) Other comprehensive income (loss): Foreign currency translation adjustment (11,274 ) (8,724 ) (8,611 ) 17,335 (11,274 ) Total other comprehensive income (loss) (11,274 ) (8,724 ) (8,611 ) 17,335 (11,274 ) Total comprehensive income (loss) (59,499 ) (19,957 ) (8,621 ) 28,587 (59,490 ) Less: Net (income) loss attributable to the noncontrolling interest — — (9 ) — (9 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (59,499 ) $ (19,957 ) $ (8,630 ) $ 28,587 $ (59,499 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS For the Nine Months Ended September 30, 2015 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net income (loss) $ (82,004 ) $ 31,607 $ 17,270 $ (48,273 ) $ (81,400 ) Other comprehensive income (loss): Foreign currency translation adjustment (5,617 ) (5,582 ) (4,687 ) 10,269 (5,617 ) Total other comprehensive income (loss) (5,617 ) (5,582 ) (4,687 ) 10,269 (5,617 ) Total comprehensive income (loss) (87,621 ) 26,025 12,583 (38,004 ) (87,017 ) Less: Net (income) loss attributable to the noncontrolling interest — — (604 ) — (604 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (87,621 ) $ 26,025 $ 11,979 $ (38,004 ) $ (87,621 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS For the Nine Months Ended September 30, 2014 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net income (loss) $ (150,458 ) $ (61,475 ) $ 7,288 $ 54,716 $ (149,929 ) Other comprehensive income (loss): Foreign currency translation adjustment (8,584 ) (7,382 ) (7,459 ) 14,841 (8,584 ) Total other comprehensive income (loss) (8,584 ) (7,382 ) (7,459 ) 14,841 (8,584 ) Total comprehensive income (loss) (159,042 ) (68,857 ) (171 ) 69,557 (158,513 ) Less: Net (income) loss attributable to the noncontrolling interest — — (529 ) — (529 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (159,042 ) $ (68,857 ) $ (700 ) $ 69,557 $ (159,042 ) CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2015 (in thousands) inVentiv Guarantor Non- Guarantor– Subsidiaries Eliminations Total Cash flows from operating activities: Net cash provided by (used in) operating activities $ (113,073 ) $ 141,330 $ 37,789 $ (12,728 ) $ 53,318 Cash flows from investing activities: Purchases of property and equipment (8,530 ) (15,292 ) (4,797 ) — (28,619 ) Proceeds from sale of business 10,691 — — — 10,691 Proceeds from vehicle sales — 6,413 — — 6,413 Proceeds from life insurance distribution 1,800 — — — 1,800 Return of (disbursements for) investments 224 — — — 224 Intercompany transfers 159,339 3,408 — (162,747 ) — Other, net 17 5,271 (305 ) — 4,983 Net cash provided by (used in) investing activities 163,541 (200 ) (5,102 ) (162,747 ) (4,508 ) Cash flows from financing activities: Repayments on capital leases — (19,863 ) (311 ) — (20,174 ) Borrowings under line of credit 153,000 — — — 153,000 Repayments on line of credit (153,000 ) — — — (153,000 ) Payment on installment note related to acquisition (1,750 ) — — — (1,750 ) Payment of debt issuance costs (324 ) — — — (324 ) Repayment of other financing arrangements (2,175 ) (352 ) — — (2,527 ) Intercompany transfers — (124,354 ) 1,451 122,903 — Other, net (353 ) — (576 ) — (929 ) Net cash provided by (used in) financing activities (4,602 ) (144,569 ) 564 122,903 (25,704 ) Effects of foreign currency exchange rate changes on cash — — (159 ) — (159 ) Net increase (decrease) in cash and cash equivalents 45,866 (3,439 ) 33,092 (52,572 ) 22,947 Cash and cash equivalents, beginning of period 19,643 3,439 86,014 (52,037 ) 57,059 Cash and cash equivalents, end of period $ 65,509 $ — $ 119,106 $ (104,609 ) $ 80,006 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2014 (in thousands) inVentiv Guarantor Non- Guarantor– Subsidiaries Eliminations Total Cash flows from operating activities: Net cash provided by (used in) continuing operations $ (143,327 ) $ 60,391 $ 4,090 $ — $ (78,846 ) Net cash provided by (used in) discontinued operations — (7,435 ) — — (7,435 ) Net cash provided by (used in) operating activities (143,327 ) 52,956 4,090 — (86,281 ) Cash flows from investing activities: Purchases of property and equipment (9,760 ) (10,115 ) (4,375 ) — (24,250 ) Proceeds from vehicle sales — 3,785 — — 3,785 Return of (disbursements for) investments (2,625 ) — — — (2,625 ) Intercompany transfers 86,267 25,568 — (111,835 ) — Other, net (62 ) 3,268 — — 3,206 Net cash provided by (used in) investing activities 73,820 22,506 (4,375 ) (111,835 ) (19,884 ) Cash flows from financing activities: Repayments on capital leases — (12,073 ) (132 ) — (12,205 ) Borrowings under line of credit 262,000 — — — 262,000 Repayments on line of credit (262,000 ) — — — (262,000 ) Payment on installment note related to acquisition (1,500 ) — — — (1,500 ) Proceeds from issuances of debt 50,000 — — — 50,000 Payments of debt issuance costs (2,319 ) — — — (2,319 ) Repayment of debt and other financing arrangements (2,821 ) (704 ) — — (3,525 ) Intercompany transfers — (75,654 ) 1,817 73,837 — Other, net 154 — (584 ) — (430 ) Net cash provided by (used in) financing activities 43,514 (88,431 ) 1,101 73,837 30,021 Effects of foreign currency exchange rate changes on cash — — (5,291 ) — (5,291 ) Net increase (decrease) in cash and cash equivalents (25,993 ) (12,969 ) (4,475 ) (37,998 ) (81,435 ) Cash and cash equivalents, beginning of period 33,176 19,838 98,457 (35,244 ) 116,227 Cash and cash equivalents, end of period $ 7,183 $ 6,869 $ 93,982 $ (73,242 ) $ 34,792

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Results of Discontinued Operations	The following table sets forth the results of the discontinued operations (in thousands): Nine Months September 30, Net revenues $ 3,254 Pre-tax income (loss) from discontinued operations (8,163 ) Income tax (provision) benefit from discontinued operations — Net income (loss) from discontinued operations (8,163 )

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Carrying Amount of Goodwill	The following table sets forth the carrying amount of goodwill as of September 30, 2015 and December 31, 2014 (in thousands): Clinical Commercial Total Net goodwill at December 31, 2014 $ 382,316 $ 549,471 $ 931,787 Foreign currency translation (79 ) (1,682 ) (1,761 ) Net goodwill at September 30, 2015 $ 382,237 $ 547,789 $ 930,026

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Amount of Intangible Assets	The following table sets forth the carrying amount of the Company’s intangible assets as of September 30, 2015 and December 31, 2014 (in thousands): September 30, 2015 December 31, 2014 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Customer relationships $ 404,042 $ (153,228 ) $ 250,814 $ 405,021 $ (128,510 ) $ 276,511 Technology 27,561 (26,515 ) 1,046 27,832 (23,442 ) 4,390 Tradenames subject to amortization 24,206 (20,128 ) 4,078 24,505 (18,513 ) 5,992 Backlog 95,015 (87,434 ) 7,581 95,015 (80,447 ) 14,568 Other 1,020 (555 ) 465 1,020 (465 ) 555 Total finite-lived intangible assets 551,844 (287,860 ) 263,984 553,393 (251,377 ) 302,016 Tradenames not subject to amortization 115,802 — 115,802 115,808 — 115,808 Total intangible assets $ 667,646 $ (287,860 ) $ 379,786 $ 669,201 $ (251,377 ) $ 417,824

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Summary of Debt	The Company’s indebtedness is summarized as follows (in thousands): September 30, 2015 December 31, 2014 Senior Secured Credit Facilities: Term Loan Facility B3 loans, due 2018 $ 129,645 $ 129,645 Term Loan Facility B4 loans, due 2018 445,694 445,694 Senior Secured Notes, due 2018 625,392 625,489 ABL Facility — — Junior Lien Secured Notes, due 2018 564,291 500,265 Senior Notes, due 2018 371,446 370,139 International Facility — — Capital leases and other financing arrangements 55,397 45,589 Total borrowings 2,191,865 2,116,821 Less: current portion of capital leases and other financing arrangements 19,390 16,265 Total long-term borrowings, net of current portion $ 2,172,475 $ 2,100,556
Summary of Carrying Amounts and Estimated Fair Values of Long-Term Debt	The carrying amounts and the estimated fair values of long-term debt as of September 30, 2015 and December 31, 2014 are as follows (in thousands): September 30, 2015 December 31, 2014 Carrying value Estimated fair value Carrying value Estimated fair value Term Loan Facility $ 575,339 $ 572,463 $ 575,339 $ 571,024 Senior Secured Notes 625,392 644,154 625,489 637,217 Junior Lien Secured Notes 564,291 560,764 500,265 463,370 Senior Notes 371,446 358,910 370,139 322,569

Termination Benefits and Othe28

Termination Benefits and Other Cost Reduction Actions (Tables)	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Summary of Real Estate Consolidations, Elimination of Redundant Functions and Employees Expenses	Expenses related to these actions, which include real estate consolidations, elimination of redundant functions and employees, were summarized below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Employee severance and related costs $ 4,117 $ 1,976 $ 10,241 $ 8,947 Facilities-related costs 601 123 932 3,797 Total $ 4,718 $ 2,099 $ 11,173 $ 12,744
Summary of Company's Restructuring Reserve	The following table summarizes the Company’s restructuring reserve as of September 30, 2015 and December 31, 2014 (in thousands): Balance at December 31, 2014 Net Costs Cash Payments Balance at September 30, 2015 Employee severance and related costs $ 5,145 $ 10,241 $ (10,291 ) $ 5,095 Facilities-related charges 7,098 932 (4,846 ) 3,184 Total $ 12,243 $ 11,173 $ (15,137 ) $ 8,279

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Schedule of Selected Information for Each Reportable Segment	Selected information for each reportable segment is as follows (in thousands): Three Months Ended Nine Months Ended 2015 2014 2015 2014 Net Revenues Clinical $ 244,570 $ 215,695 $ 697,816 $ 648,669 Commercial 279,147 248,242 773,155 689,989 Intersegment revenues (2,307 ) (1,546 ) (9,167 ) (4,893 ) Consolidated net revenues $ 521,410 $ 462,391 $ 1,461,804 $ 1,333,765 Adjusted Segment Operating Income (Loss) Clinical $ 38,713 $ 25,140 $ 92,831 $ 70,002 Commercial 46,312 35,146 121,177 87,313 Corporate and other (10,908 ) (10,050 ) (29,842 ) (20,372 ) Reportable segments adjusted operating income (loss) 74,117 50,236 184,166 136,943 Depreciation and amortization (23,625 ) (26,555 ) (72,536 ) (80,137 ) Stock-based compensation (1,632 ) 22 (2,147 ) (422 ) Other unallocated charges (4,941 ) (4,554 ) (18,374 ) (17,167 ) Operating income (loss) $ 43,919 $ 19,149 $ 91,109 $ 39,217 Loss on extinguishment of debt and refinancing costs — (10,062 ) — (10,062 ) Interest income (expense), net (57,294 ) (54,988 ) (170,877 ) (160,672 ) Other income 11,318 — 11,318 — Income (loss) before income tax (provision) benefit and income (loss) from equity investments. $ (2,057 ) $ (45,901 ) $ (68,450 ) $ (131,517 )

Guarantor Financial Informati30

Guarantor Financial Information (Tables)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Condensed Consolidating Balance Sheet Information	CONDENSED CONSOLIDATING BALANCE SHEET INFORMATION At September 30, 2015 (in thousands, except share and per share amounts) inVentiv Guarantor Non- Guarantor Eliminations Total ASSETS Current assets: Cash and cash equivalents $ 65,509 $ — $ 119,106 $ (104,609 ) $ 80,006 Restricted cash 553 — 1,419 — 1,972 Accounts receivable, net of allowances for doubtful accounts — 252,143 55,905 — 308,048 Unbilled services — 196,521 43,496 — 240,017 Intercompany receivables 488,420 749,921 93,234 (1,331,575 ) — Prepaid expenses and other current assets 8,541 15,111 19,987 — 43,639 Income tax receivable 85 502 930 — 1,517 Current deferred tax assets 259 12,198 1,586 (6,261 ) 7,782 Total current assets 563,367 1,226,396 335,663 (1,442,445 ) 682,981 Property and equipment, net 23,170 90,853 15,747 — 129,770 Goodwill — 889,281 40,745 — 930,026 Intangible assets, net — 373,101 6,685 — 379,786 Non-current deferred tax assets — — 3,824 — 3,824 Deferred financing costs and other assets 51,690 12,624 15,032 — 79,346 Non-current intercompany receivables 403,917 29,625 136 (433,678 ) — Investment in consolidated subsidiaries 728,742 92,458 — (821,200 ) — Total assets $ 1,770,886 $ 2,714,338 $ 417,832 $ (2,697,323 ) $ 2,205,733 LIABILITIES AND STOCKHOLDER’S DEFICIT Current liabilities: Current portion of capital lease obligations and other financing arrangements $ — $ 19,266 $ 92,005 $ (91,881 ) $ 19,390 Accrued payroll, accounts payable and accrued expenses 80,456 190,314 60,866 (12,728 ) 318,908 Intercompany payables 809,634 501,879 20,062 (1,331,575 ) — Income taxes payable — 75 2,725 — 2,800 Deferred revenue and client advances — 174,532 54,953 — 229,485 Total current liabilities 890,090 886,066 230,611 (1,436,184 ) 570,583 Capital lease obligations, net of current portion — 35,971 36 — 36,007 Long-term debt, net of current portion 1,560,129 576,339 — — 2,136,468 Non-current income tax liability — 5,543 1,209 — 6,752 Deferred tax liability 333 86,659 3,844 (6,261 ) 84,575 Other non-current liabilities 20,989 31,362 18,230 — 70,581 Non-current intercompany liabilities — 404,050 29,628 (433,678 ) — Total liabilities 2,471,541 2,025,990 283,558 (1,876,123 ) 2,904,966 Total inVentiv Health, Inc. stockholder’s deficit (700,655 ) 688,348 132,852 (821,200 ) (700,655 ) Noncontrolling interest — — 1,422 — 1,422 Total stockholder’s deficit (700,655 ) 688,348 134,274 (821,200 ) (699,233 ) Total liabilities and stockholder’s deficit $ 1,770,886 $ 2,714,338 $ 417,832 $ (2,697,323 ) $ 2,205,733 CONDENSED CONSOLIDATING BALANCE SHEET INFORMATION At December 31, 2014 (in thousands, except share and per share amounts) inVentiv Guarantor Non- Guarantor Eliminations Total ASSETS Current assets: Cash and cash equivalents $ 19,643 $ 3,439 $ 86,014 $ (52,037 ) $ 57,059 Restricted cash 569 — 1,148 — 1,717 Accounts receivable, net of allowances for doubtful accounts — 236,884 65,963 — 302,847 Unbilled services — 138,100 40,936 — 179,036 Intercompany receivables 375,025 557,758 64,778 (997,561 ) — Prepaid expenses and other current assets 5,301 12,181 20,743 — 38,225 Income tax receivable — 310 1,053 — 1,363 Current deferred tax assets 259 12,198 1,316 (6,261 ) 7,512 Total current assets 400,797 960,870 281,951 (1,055,859 ) 587,759 Property and equipment, net 21,665 82,857 17,337 — 121,859 Goodwill — 889,281 42,506 — 931,787 Intangible assets, net — 410,059 7,765 — 417,824 Non-current deferred tax assets — — 3,944 — 3,944 Deferred financing costs and other assets 64,484 14,331 12,447 — 91,262 Non-current intercompany receivables 368,325 38,847 132 (407,304 ) — Investment in consolidated subsidiaries 700,383 86,242 — (786,625 ) — Total assets $ 1,555,654 $ 2,482,487 $ 366,082 $ (2,249,788 ) $ 2,154,435 LIABILITIES AND STOCKHOLDER’S DEFICIT Current liabilities: Current portion of capital lease obligations and other financing arrangements $ 4,006 $ 14,025 $ 50,271 $ (52,037 ) $ 16,265 Accrued payroll, accounts payable and accrued expenses 62,179 162,937 61,497 — 286,613 Intercompany payables 562,297 404,413 30,851 (997,561 ) — Income taxes payable 222 — 987 — 1,209 Deferred revenue and client advances — 150,709 48,421 — 199,130 Total current liabilities 628,704 732,084 192,027 (1,049,598 ) 503,217 Capital lease obligations, net of current portion — 29,126 198 — 29,324 Long-term debt, net of current portion 1,494,893 576,339 — — 2,071,232 Non-current income tax liability — 5,360 1,101 — 6,461 Deferred tax liability 333 80,860 2,300 (6,261 ) 77,232 Other non-current liabilities 37,441 25,175 18,140 — 80,756 Non-current intercompany liabilities 9,464 368,457 29,383 (407,304 ) — Total liabilities 2,170,835 1,817,401 243,149 (1,463,163 ) 2,768,222 Total inVentiv Health, Inc. stockholder’s deficit (615,181 ) 665,086 121,539 (786,625 ) (615,181 ) Noncontrolling interest — — 1,394 — 1,394 Total stockholder’s deficit (615,181 ) 665,086 122,933 (786,625 ) (613,787 ) Total liabilities and stockholder’s deficit $ 1,555,654 $ 2,482,487 $ 366,082 $ (2,249,788 ) $ 2,154,435
Schedule of Consolidating Statement of Operations	CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended September 30, 2015 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net revenues $ — $ 408,448 $ 119,469 $ (6,507 ) $ 521,410 Reimbursed out-of-pocket expenses — 77,745 10,290 (104 ) 87,931 Total revenues — 486,193 129,759 (6,611 ) 609,341 Operating expenses: Cost of revenues — 271,754 70,895 (5,896 ) 336,753 Reimbursable out-of-pocket expenses — 77,745 10,290 (104 ) 87,931 Selling, general and administrative expenses 22,866 88,264 30,219 (611 ) 140,738 Allocation of intercompany costs (9,854 ) 7,886 1,968 — — Total operating expenses 13,012 445,649 113,372 (6,611 ) 565,422 Operating income (loss) (13,012 ) 40,544 16,387 — 43,919 Interest income (expense), net (44,994 ) (12,445 ) 145 — (57,294 ) Other income 11,318 — — — 11,318 Intercompany interest income (expense) 12,342 (12,025 ) (317 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (34,346 ) 16,074 16,215 — (2,057 ) Income tax (provision) benefit — (1,488 ) (2,907 ) — (4,395 ) Income (loss) before income (loss) from equity investments (34,346 ) 14,586 13,308 — (6,452 ) Income (loss) from equity investments 27,658 10,728 — (38,384 ) 2 Net income (loss) (6,688 ) 25,314 13,308 (38,384 ) (6,450 ) Less: Net (income) loss attributable to the noncontrolling interest — — (238 ) — (238 ) Net income (loss) attributable to inVentiv Health, Inc. $ (6,688 ) $ 25,314 $ 13,070 $ (38,384 ) $ (6,688 ) CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended September 30, 2014 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net revenues $ — $ 346,452 $ 122,277 $ (6,338 ) $ 462,391 Reimbursed out-of-pocket expenses — 49,283 13,207 (30 ) 62,460 Total revenues — 395,735 135,484 (6,368 ) 524,851 Operating expenses: Cost of revenues — 228,411 79,907 (5,929 ) 302,389 Reimbursable out-of-pocket expenses — 49,283 13,207 (30 ) 62,460 Selling, general and administrative expenses 13,892 89,727 37,643 (409 ) 140,853 Allocation of intercompany costs (11,743 ) 8,960 2,783 — — Total operating expenses 2,149 376,381 133,540 (6,368 ) 505,702 Operating income (loss) (2,149 ) 19,354 1,944 — 19,149 Loss on extinguishment of debt and refinancing costs (3,570 ) (6,492 ) — — (10,062 ) Interest income (expense), net (42,273 ) (12,759 ) 44 — (54,988 ) Intercompany interest income (expense) 10,767 (10,157 ) (610 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (37,225 ) (10,054 ) 1,378 — (45,901 ) Income tax (provision) benefit — (893 ) (1,388 ) — (2,281 ) Income (loss) before income (loss) from equity investments (37,225 ) (10,947 ) (10 ) — (48,182 ) Income (loss) from equity investments (11,000 ) (286 ) — 11,252 (34 ) Net income (loss) (48,225 ) (11,233 ) (10 ) 11,252 (48,216 ) Less: Net (income) loss attributable to the noncontrolling interest — — (9 ) — (9 ) Net income (loss) attributable to inVentiv Health, Inc. $ (48,225 ) $ (11,233 ) $ (19 ) $ 11,252 $ (48,225 ) CONSOLIDATING STATEMENT OF OPERATIONS Nine Months Ended September 30, 2015 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net revenues $ — $ 1,138,337 $ 342,147 $ (18,680 ) $ 1,461,804 Reimbursed out-of-pocket expenses — 205,811 32,762 (242 ) 238,331 Total revenues — 1,344,148 374,909 (18,922 ) 1,700,135 Operating expenses: Cost of revenues — 750,784 212,579 (17,043 ) 946,320 Reimbursable out-of-pocket expenses — 205,811 32,762 (242 ) 238,331 Selling, general and administrative expenses 59,444 266,007 100,561 (1,637 ) 424,375 Allocation of intercompany costs (29,654 ) 23,765 5,889 — — Total operating expenses 29,790 1,246,367 351,791 (18,922 ) 1,609,026 Operating income (loss) (29,790 ) 97,781 23,118 — 91,109 Interest income (expense), net (134,399 ) (36,892 ) 414 — (170,877 ) Other income 11,318 — — — 11,318 Intercompany interest income (expense) 35,265 (34,551 ) (714 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (117,606 ) 26,338 22,818 — (68,450 ) Income tax (provision) benefit — (6,113 ) (5,548 ) — (11,661 ) Income (loss) before income (loss) from equity investments (117,606 ) 20,225 17,270 — (80,111 ) Income (loss) from equity investments 35,602 11,382 — (48,273 ) (1,289 ) Net income (loss) (82,004 ) 31,607 17,270 (48,273 ) (81,400 ) Less: Net (income) loss attributable to the noncontrolling interest — — (604 ) — (604 ) Net income (loss) attributable to inVentiv Health, Inc. $ (82,004 ) $ 31,607 $ 16,666 $ (48,273 ) $ (82,004 ) CONSOLIDATING STATEMENT OF OPERATIONS Nine Months Ended September 30, 2014 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net revenues $ — $ 989,307 $ 376,158 $ (31,700 ) $ 1,333,765 Reimbursed out-of-pocket expenses — 143,347 39,739 (271 ) 182,815 Total revenues — 1,132,654 415,897 (31,971 ) 1,516,580 Operating expenses: Cost of revenues — 656,655 242,731 (30,027 ) 869,359 Reimbursable out-of-pocket expenses — 143,347 39,739 (271 ) 182,815 Selling, general and administrative expenses 31,693 282,328 112,841 (1,673 ) 425,189 Allocation of intercompany costs (35,229 ) 26,853 8,376 — — Total operating expenses (3,536 ) 1,109,183 403,687 (31,971 ) 1,477,363 Operating income (loss) 3,536 23,471 12,210 — 39,217 Loss on extinguishment of debt and refinancing costs (3,570 ) (6,492 ) — — (10,062 ) Interest income (expense), net (122,959 ) (38,000 ) 287 — (160,672 ) Intercompany interest income (expense) 31,265 (29,324 ) (1,941 ) — — Income (loss) before income tax (provision) benefit and income (loss) from equity investments (91,728 ) (50,345 ) 10,556 — (131,517 ) Income tax (provision) benefit (127 ) (6,584 ) (3,268 ) — (9,979 ) Income (loss) before income (loss) from equity investments (91,855 ) (56,929 ) 7,288 — (141,496 ) Income (loss) from equity investments (58,603 ) 3,617 — 54,716 (270 ) Income (loss) from continuing operations (150,458 ) (53,312 ) 7,288 54,716 (141,766 ) Net income (loss) from discontinued operations, net of tax — (8,163 ) — — (8,163 ) Net income (loss) (150,458 ) (61,475 ) 7,288 54,716 (149,929 ) Less: Net (income) loss attributable to the noncontrolling interest — — (529 ) — (529 ) Net income (loss) attributable to inVentiv Health, Inc. $ (150,458 ) $ (61,475 ) $ 6,759 $ 54,716 $ (150,458 )
Schedule of Consolidating Statement of Comprehensive Loss	CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS For the Three Months Ended September 30, 2015 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net income (loss) $ (6,688 ) $ 25,314 $ 13,308 $ (38,384 ) $ (6,450 ) Other comprehensive income (loss): Foreign currency translation adjustment (4,390 ) (5,260 ) (3,272 ) 8,532 (4,390 ) Total other comprehensive income (loss) (4,390 ) (5,260 ) (3,272 ) 8,532 (4,390 ) Total comprehensive income (loss) (11,078 ) 20,054 10,036 (29,852 ) (10,840 ) Less: Net (income) loss attributable to the noncontrolling interest — — (238 ) — (238 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (11,078 ) $ 20,054 $ 9,798 $ (29,852 ) $ (11,078 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS For the Three Months Ended September 30, 2014 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net income (loss) $ (48,225 ) $ (11,233 ) $ (10 ) $ 11,252 $ (48,216 ) Other comprehensive income (loss): Foreign currency translation adjustment (11,274 ) (8,724 ) (8,611 ) 17,335 (11,274 ) Total other comprehensive income (loss) (11,274 ) (8,724 ) (8,611 ) 17,335 (11,274 ) Total comprehensive income (loss) (59,499 ) (19,957 ) (8,621 ) 28,587 (59,490 ) Less: Net (income) loss attributable to the noncontrolling interest — — (9 ) — (9 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (59,499 ) $ (19,957 ) $ (8,630 ) $ 28,587 $ (59,499 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS For the Nine Months Ended September 30, 2015 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net income (loss) $ (82,004 ) $ 31,607 $ 17,270 $ (48,273 ) $ (81,400 ) Other comprehensive income (loss): Foreign currency translation adjustment (5,617 ) (5,582 ) (4,687 ) 10,269 (5,617 ) Total other comprehensive income (loss) (5,617 ) (5,582 ) (4,687 ) 10,269 (5,617 ) Total comprehensive income (loss) (87,621 ) 26,025 12,583 (38,004 ) (87,017 ) Less: Net (income) loss attributable to the noncontrolling interest — — (604 ) — (604 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (87,621 ) $ 26,025 $ 11,979 $ (38,004 ) $ (87,621 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE LOSS For the Nine Months Ended September 30, 2014 (in thousands) inVentiv Guarantor Non- Guarantor Eliminations Total Net income (loss) $ (150,458 ) $ (61,475 ) $ 7,288 $ 54,716 $ (149,929 ) Other comprehensive income (loss): Foreign currency translation adjustment (8,584 ) (7,382 ) (7,459 ) 14,841 (8,584 ) Total other comprehensive income (loss) (8,584 ) (7,382 ) (7,459 ) 14,841 (8,584 ) Total comprehensive income (loss) (159,042 ) (68,857 ) (171 ) 69,557 (158,513 ) Less: Net (income) loss attributable to the noncontrolling interest — — (529 ) — (529 ) Total comprehensive income (loss) attributable to inVentiv Health, Inc. $ (159,042 ) $ (68,857 ) $ (700 ) $ 69,557 $ (159,042 )
Schedule of Condensed Consolidating Statement of Cash Flows	CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2015 (in thousands) inVentiv Guarantor Non- Guarantor– Subsidiaries Eliminations Total Cash flows from operating activities: Net cash provided by (used in) operating activities $ (113,073 ) $ 141,330 $ 37,789 $ (12,728 ) $ 53,318 Cash flows from investing activities: Purchases of property and equipment (8,530 ) (15,292 ) (4,797 ) — (28,619 ) Proceeds from sale of business 10,691 — — — 10,691 Proceeds from vehicle sales — 6,413 — — 6,413 Proceeds from life insurance distribution 1,800 — — — 1,800 Return of (disbursements for) investments 224 — — — 224 Intercompany transfers 159,339 3,408 — (162,747 ) — Other, net 17 5,271 (305 ) — 4,983 Net cash provided by (used in) investing activities 163,541 (200 ) (5,102 ) (162,747 ) (4,508 ) Cash flows from financing activities: Repayments on capital leases — (19,863 ) (311 ) — (20,174 ) Borrowings under line of credit 153,000 — — — 153,000 Repayments on line of credit (153,000 ) — — — (153,000 ) Payment on installment note related to acquisition (1,750 ) — — — (1,750 ) Payment of debt issuance costs (324 ) — — — (324 ) Repayment of other financing arrangements (2,175 ) (352 ) — — (2,527 ) Intercompany transfers — (124,354 ) 1,451 122,903 — Other, net (353 ) — (576 ) — (929 ) Net cash provided by (used in) financing activities (4,602 ) (144,569 ) 564 122,903 (25,704 ) Effects of foreign currency exchange rate changes on cash — — (159 ) — (159 ) Net increase (decrease) in cash and cash equivalents 45,866 (3,439 ) 33,092 (52,572 ) 22,947 Cash and cash equivalents, beginning of period 19,643 3,439 86,014 (52,037 ) 57,059 Cash and cash equivalents, end of period $ 65,509 $ — $ 119,106 $ (104,609 ) $ 80,006 CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2014 (in thousands) inVentiv Guarantor Non- Guarantor– Subsidiaries Eliminations Total Cash flows from operating activities: Net cash provided by (used in) continuing operations $ (143,327 ) $ 60,391 $ 4,090 $ — $ (78,846 ) Net cash provided by (used in) discontinued operations — (7,435 ) — — (7,435 ) Net cash provided by (used in) operating activities (143,327 ) 52,956 4,090 — (86,281 ) Cash flows from investing activities: Purchases of property and equipment (9,760 ) (10,115 ) (4,375 ) — (24,250 ) Proceeds from vehicle sales — 3,785 — — 3,785 Return of (disbursements for) investments (2,625 ) — — — (2,625 ) Intercompany transfers 86,267 25,568 — (111,835 ) — Other, net (62 ) 3,268 — — 3,206 Net cash provided by (used in) investing activities 73,820 22,506 (4,375 ) (111,835 ) (19,884 ) Cash flows from financing activities: Repayments on capital leases — (12,073 ) (132 ) — (12,205 ) Borrowings under line of credit 262,000 — — — 262,000 Repayments on line of credit (262,000 ) — — — (262,000 ) Payment on installment note related to acquisition (1,500 ) — — — (1,500 ) Proceeds from issuances of debt 50,000 — — — 50,000 Payments of debt issuance costs (2,319 ) — — — (2,319 ) Repayment of debt and other financing arrangements (2,821 ) (704 ) — — (3,525 ) Intercompany transfers — (75,654 ) 1,817 73,837 — Other, net 154 — (584 ) — (430 ) Net cash provided by (used in) financing activities 43,514 (88,431 ) 1,101 73,837 30,021 Effects of foreign currency exchange rate changes on cash — — (5,291 ) — (5,291 ) Net increase (decrease) in cash and cash equivalents (25,993 ) (12,969 ) (4,475 ) (37,998 ) (81,435 ) Cash and cash equivalents, beginning of period 33,176 19,838 98,457 (35,244 ) 116,227 Cash and cash equivalents, end of period $ 7,183 $ 6,869 $ 93,982 $ (73,242 ) $ 34,792

Organization and Business - Add

Organization and Business - Additional Information (Detail) $ in Thousands	Aug. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)SegmentCompanyOrganization	Sep. 30, 2014USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of reportable segments | Segment				2
Number of global pharmaceutical companies | Company				20
Gain on sale of business				$ 11,318
Net revenues		$ 521,410	$ 462,391	$ 1,461,804	$ 1,333,765
Minimum [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of client organizations | Organization				550
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | inVentiv Patient Access Solutions ("IPAS") [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net revenues				$ 11,900	$ 11,800
Other Income [Member] | inVentiv Patient Access Solutions ("IPAS") [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Gain on sale of business	$ 11,300

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Minority interest owned percentage	60.00%
Recognized loss on dissolution of a joint venture	$ (1.3)

Discontinued Operations - Sched

Discontinued Operations - Schedule of Results of Discontinued Operations (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2014USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Net revenues	$ 3,254
Pre-tax income (loss) from discontinued operations	(8,163)
Income tax (provision) benefit from discontinued operations	0
Net income (loss) from discontinued operations	$ (8,163)

Goodwill - Schedule of Carrying

Goodwill - Schedule of Carrying Amount of Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill [Line Items]
Net goodwill, Beginning balance	$ 931,787
Foreign currency translation	(1,761)
Net goodwill, Ending balance	930,026
Clinical [Member]
Goodwill [Line Items]
Net goodwill, Beginning balance	382,316
Foreign currency translation	(79)
Net goodwill, Ending balance	382,237
Commercial [Member]
Goodwill [Line Items]
Net goodwill, Beginning balance	549,471
Foreign currency translation	(1,682)
Net goodwill, Ending balance	$ 547,789

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Accumulated goodwill impairment losses	$ 444.3	$ 444.3

Intangible Assets - Schedule of

Intangible Assets - Schedule of Carrying Amount of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	$ 551,844	$ 553,393
Intangible assets, Gross	667,646	669,201
Finite-lived intangible assets, Accumulated Amortization	(287,860)	(251,377)
Finite-lived intangible assets, Net	263,984	302,016
Intangible assets, net	379,786	417,824
Tradenames [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, Gross	115,802	115,808
Indefinite-lived intangible assets, Net	115,802	115,808
Customer Relationships [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	404,042	405,021
Finite-lived intangible assets, Accumulated Amortization	(153,228)	(128,510)
Finite-lived intangible assets, Net	250,814	276,511
Technology [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	27,561	27,832
Finite-lived intangible assets, Accumulated Amortization	(26,515)	(23,442)
Finite-lived intangible assets, Net	1,046	4,390
Tradenames [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	24,206	24,505
Finite-lived intangible assets, Accumulated Amortization	(20,128)	(18,513)
Finite-lived intangible assets, Net	4,078	5,992
Backlog [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	95,015	95,015
Finite-lived intangible assets, Accumulated Amortization	(87,434)	(80,447)
Finite-lived intangible assets, Net	7,581	14,568
Other [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	1,020	1,020
Finite-lived intangible assets, Accumulated Amortization	(555)	(465)
Finite-lived intangible assets, Net	$ 465	$ 555

Debt - Summary of Debt (Detail)

Debt - Summary of Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Total borrowings	$ 2,191,865	$ 2,116,821
Less: current portion of capital leases and other financing arrangements	19,390	16,265
Total long-term borrowings, net of current portion	2,172,475	2,100,556
Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Total borrowings	575,300
Senior Secured Credit Facilities [Member] | Term Loan Facility B3 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings	129,645	129,645
Senior Secured Credit Facilities [Member] | Term Loan Facility B4 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings	445,694	445,694
Senior Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings	625,392	625,489
Junior Lien Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings	564,291	500,265
Senior Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Total borrowings	371,446	370,139
Capital Leases and Other Financing Arrangements [Member]
Debt Instrument [Line Items]
Total borrowings	$ 55,397	$ 45,589

Debt - Summary of Debt (Parenth

Debt - Summary of Debt (Parenthetical) (Detail)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Senior Secured Credit Facilities [Member] | Term Loan Facility B3 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Maturity year	2,018	2,018
Senior Secured Credit Facilities [Member] | Term Loan Facility B4 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Maturity year	2,018	2,018
Senior Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Maturity year	2,018	2,018
Junior Lien Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Maturity year	2,018	2,018
Senior Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Maturity year	2,018	2,018

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Aug. 15, 2014	Aug. 12, 2014	Aug. 16, 2013	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Jul. 01, 2015
Debt Instrument [Line Items]
Debt instrument, outstanding amount					$ 2,191,865,000		$ 2,116,821,000
New Money Investment						$ 50,000,000
Loss on extinguishment of debt and refinancing costs						$ (3,537,000)
Net cash position in cash pool					8,400,000
Gross cash position in cash pool					100,300,000
Cash pool borrowings					$ 91,900,000
Junior Lien Notes Exchange Offer [Member]
Debt Instrument [Line Items]
Debt instrument, total consideration		$ 50,000,000
Increase in margin of the term loan					0.25%
Loss on extinguishment of debt and refinancing costs				$ (10,100,000)
Junior Lien Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, outstanding amount					$ 564,291,000		$ 500,265,000
Original issuance discount					$ 5,400,000
Debt instrument, maturity year					2,018		2,018
Junior Lien Secured Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Debt Instrument [Line Items]
Debt instrument, maturity year	2,018
Description of interest payment period by issuance of additional Junior Lien Secured Notes					Six semi-annual interest payments
Debt instrument, cash interest rate	10.00%
Debt instrument, PIK interest rate	12.00%				12.00%
Junior lien secured notes issued		25,000,000
New Money Investment	$ 7,000,000
Senior Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, outstanding amount					$ 371,446,000		$ 370,139,000
Original issuance discount					$ 4,900,000
Debt instrument, maturity year					2,018		2,018
Senior Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Debt Instrument [Line Items]
Original issuance discount		$ 1,300,000
Debt instrument, interest rate		10.00%
Debt instrument, interest rate of Junior Lien Secured Notes	10%/12%
Debt instrument, maturity year	2,018	2,018
Exchange Offer Amount	$ 475,000,000
Debt instrument, total consideration		$ 26,300,000
Debt instrument, discount percentage		5.00%
ABL Facility [Member]
Debt Instrument [Line Items]
Debt instrument, outstanding amount					$ 0
Debt instrument, interest rate					4.25%
Line of credit facility, description					Amounts borrowed under the ABL Facility are subject to interest at a rate per annum equal to an applicable margin plus, at the Company's option, either (a) a base rate determined by reference to the highest of (i) the Federal Funds Rate plus .5%, (ii) the prime rate of Citibank, N.A., or (iii) the one month US Dollar LIBOR rate plus 1.0% or (b) the US Dollar LIBOR rate based on the term of the borrowing.
Fixed-charge coverage ratio, description					The ABL Facility requires the Company to maintain a fixed-charge coverage ratio of at least 1.0 to 1.0 and requires certain cash management restrictions, in each case, if available borrowing capacity is less than the greater of 10% of the maximum amount that can be borrowed under the ABL Facility, based on the borrowing base at such time, and $12.0 million.
Line of Credit Facility, Covenant Terms, Minimum Percentage of Loan Cap Amount					10.00%
Line of Credit Facility, Covenant Terms, Minimum Excess Credit Availability					$ 12,000,000
Line of Credit Facility, Covenant Terms, Minimum Fixed Charge Coverage Ratio					100.00%
ABL Facility [Member] | Federal Funds Rate [Member]
Debt Instrument [Line Items]
Interest rate margin			0.50%
ABL Facility [Member] | US Dollar LIBOR Rate [Member]
Debt Instrument [Line Items]
Interest rate margin			1.00%
ABL Facility [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 150,000,000
Debt instrument, maturity date					Aug. 16, 2018
Additional borrowing capacity					$ 131,600,000
ABL Facility [Member] | Letter of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 35,000,000
Amount outstanding					$ 18,400,000
ABL Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Margin percentage for revolving loans, Base Rate					1.00%
Margin percentage for revolving loans, Eurodollar rate					2.00%
Unutilized balance rate per annum					0.25%
ABL Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Margin percentage for revolving loans, Base Rate					1.50%
Margin percentage for revolving loans, Eurodollar rate					2.50%
Unutilized balance rate per annum					0.375%
Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Debt instrument, outstanding amount					$ 575,300,000
Senior Secured Credit Facilities [Member] | Term Loan Facility B3 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, outstanding amount					$ 129,645,000		$ 129,645,000
Debt instrument, maturity year					2,018		2,018
Senior Secured Credit Facilities [Member] | Term Loan Facility B4 Loans, Due 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, outstanding amount					$ 445,694,000		$ 445,694,000
Debt instrument, maturity year					2,018		2,018
Senior Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Debt instrument, outstanding amount					$ 625,392,000		$ 625,489,000
Debt instrument, outstanding amount excluding unamortized premium					625,000,000
Unamortized premium received on issuance					$ 400,000
Debt instrument, maturity year					2,018		2,018
Capital Leases and Other Financing Arrangements [Member]
Debt Instrument [Line Items]
Debt instrument, outstanding amount					$ 55,397,000		$ 45,589,000
International ABL Facility [Member]
Debt Instrument [Line Items]
Debt instrument, outstanding amount					$ 0
Line of credit facility, maximum borrowing capacity								$ 20,000,000

Debt - Summary of Carrying Amou

Debt - Summary of Carrying Amounts and Estimated Fair Values of Long-Term Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Carrying value	$ 575,339	$ 575,339
Estimated fair value	572,463	571,024
Senior Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Carrying value	625,392	625,489
Estimated fair value	644,154	637,217
Junior Lien Secured Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Carrying value	564,291	500,265
Estimated fair value	560,764	463,370
Senior Notes, Due 2018 [Member]
Debt Instrument [Line Items]
Carrying value	371,446	370,139
Estimated fair value	$ 358,910	$ 322,569

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Master Services Agreement (MSA) [Member] - USD ($)	9 Months Ended
	Sep. 30, 2015	Jan. 31, 2015	Dec. 31, 2013
Cel-Sci Corporation versus PharmaNet [Member]
Loss Contingencies [Line Items]
Demand for arbitration	October 31, 2013
Damages claim on arbitration	$ 50,000,000
Cel Sci Corporation Versus Inventiv Health Clinical LLC [Member]
Loss Contingencies [Line Items]
Counterclaim damages on arbitration		$ 2,000,000	$ 2,000,000
Counterclaim on other equitable remedies		$ 20,000,000

Concentration of Credit Risk -

Concentration of Credit Risk - Additional Information (Detail) - Customer Concentration Risk [Member] - Customer	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Percentage of credit risk	11.00%	11.00%	10.00%	11.00%
Number of customers accounted	1	1	0	1
Accounts Receivable [Member]
Concentration Risk [Line Items]
Percentage of credit risk			10.00%
Number of customers accounted			0

Common Stock and Stock Incent43

Common Stock and Stock Incentive Plans - Additional Information (Detail) - Restricted Stock Units [Member]	Jul. 02, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
New option award terms	One-for-one
Number of shares exchanged under the equity incentive plan	156,106
Passage of Time [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting under the plan	35.00%
Performance Target [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting under the plan	65.00%

Termination Benefits and Othe44

Termination Benefits and Other Cost Reduction Actions - Summary of Real Estate Consolidations, Elimination of Redundant Functions and Employees Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring and Related Activities [Abstract]
Employee severance and related costs	$ 4,117	$ 1,976	$ 10,241	$ 8,947
Facilities-related costs	601	123	932	3,797
Total	$ 4,718	$ 2,099	$ 11,173	$ 12,744

Termination Benefits and Othe45

Termination Benefits and Other Cost Reduction Actions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 4,718	$ 2,099	$ 11,173	$ 12,744
Non cash portion of net costs related to abandoned assets			500
Cost of Revenue [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,200	1,200	4,200	2,500
Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 3,500	$ 900	$ 7,000	$ 10,200

Termination Benefits and Othe46

Termination Benefits and Other Cost Reduction Actions - Summary of Company's Restructuring Reserve (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			$ 12,243
Net Costs	$ 4,718	$ 2,099	11,173	$ 12,744
Cash Payments			(15,137)
Restructuring Reserve, Ending Balance	8,279		8,279
Employee Severance and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			5,145
Net Costs			10,241
Cash Payments			(10,291)
Restructuring Reserve, Ending Balance	5,095		5,095
Facilities-Related Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			7,098
Net Costs			932
Cash Payments			(4,846)
Restructuring Reserve, Ending Balance	$ 3,184		$ 3,184

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2015
Income Taxes [Line Items]
Consolidated effective tax rate	(213.70%)	(5.00%)	(17.00%)	(7.60%)
Scenario, Forecast [Member]
Income Taxes [Line Items]
Income tax expense related to amortization					$ 7.7
Estimated unamortized balance of tax deductible goodwill and indefinite-lived intangible assets					$ 134.7

Related Parties - Additional In

Related Parties - Additional Information (Detail)	Dec. 05, 2012USD ($)	Aug. 31, 2010USD ($)	Sep. 30, 2015USD ($)Entity	Sep. 30, 2014USD ($)Entity	Sep. 30, 2015USD ($)Entity	Sep. 30, 2014USD ($)Entity	Aug. 12, 2014USD ($)
Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Debt instrument, total consideration							$ 50,000,000
Junior Lien Secured Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Junior lien secured notes issued							$ 25,000,000
Senior Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Senior notes interest percentage							10.00%
Debt instrument, total consideration							$ 26,300,000
Blane Walter [Member]
Related Party Transaction [Line Items]
Related party transaction service amount threshold					$ 120,000
Services fees				$ 200,000	$ 1,800,000	$ 1,700,000
Minimum [Member] | Blane Walter [Member]
Related Party Transaction [Line Items]
Percentage of interest hold			10.00%		10.00%
THL [Member]
Related Party Transaction [Line Items]
Management fee description					THL Management Agreement, THL Managers will receive an aggregate annual management fee in an amount per year equal to the greater of (a) $2.5 million or (b) 1.5% of EBITDA
Annual management fee		$ 2,500,000	$ 700,000	$ 700,000	$ 2,100,000	$ 2,100,000
Percentage of management fee in EBITDA		1.50%
Number of entities | Entity			4	4	4	4
Related party transaction service amount threshold					$ 120,000
Related parties, description of transaction					THL or its affiliates held a 10% or greater interest that provided services exceeding $120,000 in value to the Company
Services fees			$ 1,200,000	$ 2,100,000	$ 3,900,000	$ 4,400,000
THL [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Percentage of interest hold			10.00%		10.00%
Liberty Lane [Member]
Related Party Transaction [Line Items]
Annual management fee	$ 800,000	$ 1,000,000		$ 200,000		$ 600,000
Affiliates of Thomas H. Lee Partners L.P., Liberty Lane and Blane Walter [Member] | Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Debt instrument, total consideration							50,000,000
Affiliates of Thomas H. Lee Partners L.P., Liberty Lane and Blane Walter [Member] | Junior Lien Secured Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Junior lien secured notes issued							$ 25,000,000
Affiliates of Thomas H. Lee Partners L.P., Liberty Lane and Blane Walter [Member] | Senior Notes, Due 2018 [Member] | Junior Lien Notes Exchange Offer [Member]
Related Party Transaction [Line Items]
Senior notes interest percentage							10.00%
Debt instrument, total consideration							$ 26,300,000

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Adjustment to earnings	$ 0.4
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amount of contingent consideration obligation	$ 1.4

Segment Information - Additiona

Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Information - Schedule

Segment Information - Schedule of Selected Information for Each Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Consolidated net revenues	$ 521,410	$ 462,391	$ 1,461,804	$ 1,333,765
Depreciation and amortization	(23,625)	(26,555)	(72,536)	(80,137)
Stock-based compensation	(1,632)	22	(2,147)	(422)
Operating expenses	(565,422)	(505,702)	(1,609,026)	(1,477,363)
Operating income (loss)	43,919	19,149	91,109	39,217
Loss on extinguishment of debt and refinancing costs		(10,062)		(10,062)
Interest income (expense), net	(57,294)	(54,988)	(170,877)	(160,672)
Other income	11,318		11,318
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	(2,057)	(45,901)	(68,450)	(131,517)
Other Unallocated Charges [Member]
Segment Reporting Information [Line Items]
Operating expenses	(4,941)	(4,554)	(18,374)	(17,167)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income (loss)	74,117	50,236	184,166	136,943
Operating Segments [Member] | Clinical [Member]
Segment Reporting Information [Line Items]
Consolidated net revenues	244,570	215,695	697,816	648,669
Operating income (loss)	38,713	25,140	92,831	70,002
Operating Segments [Member] | Commercial [Member]
Segment Reporting Information [Line Items]
Consolidated net revenues	279,147	248,242	773,155	689,989
Operating income (loss)	46,312	35,146	121,177	87,313
Operating Segments [Member] | Corporate and Other [Member]
Segment Reporting Information [Line Items]
Operating income (loss)	(10,908)	(10,050)	(29,842)	(20,372)
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Consolidated net revenues	$ (2,307)	$ (1,546)	$ (9,167)	$ (4,893)

Guarantor Financial Informati52

Guarantor Financial Information - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Condensed Financial Statements, Captions [Line Items]
Long-term debt	$ 2,191,865	$ 2,116,821
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Long-term debt	$ 575,300

Guarantor Financial Informati53

Guarantor Financial Information - Schedule of Condensed Consolidating Balance Sheet Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 80,006	$ 57,059	$ 34,792	$ 116,227
Restricted cash	1,972	1,717
Accounts receivable, net of allowances for doubtful accounts	308,048	302,847
Unbilled services	240,017	179,036
Prepaid expenses and other current assets	43,639	38,225
Income tax receivable	1,517	1,363
Current deferred tax assets	7,782	7,512
Total current assets	682,981	587,759
Property and equipment, net	129,770	121,859
Goodwill	930,026	931,787
Intangible assets, net	379,786	417,824
Non-current deferred tax assets	3,824	3,944
Deferred financing costs and other assets	79,346	91,262
Total assets	2,205,733	2,154,435
Current liabilities:
Current portion of capital lease obligations and other financing arrangements	19,390	16,265
Accrued payroll, accounts payable and accrued expenses	318,908	286,613
Income taxes payable	2,800	1,209
Deferred revenue and client advances	229,485	199,130
Total current liabilities	570,583	503,217
Capital lease obligations, net of current portion	36,007	29,324
Long-term debt, net of current portion	2,136,468	2,071,232
Non-current income tax liability	6,752	6,461
Deferred tax liability	84,575	77,232
Other non-current liabilities	70,581	80,756
Total liabilities	2,904,966	2,768,222
Total inVentiv Health, Inc. stockholder's deficit	(700,655)	(615,181)
Noncontrolling interest	1,422	1,394
Total stockholder's deficit	(699,233)	(613,787)
Total liabilities and stockholder's deficit	2,205,733	2,154,435
Eliminations [Member]
Current assets:
Cash and cash equivalents	(104,609)	(52,037)	(73,242)	(35,244)
Intercompany receivables	(1,331,575)	(997,561)
Current deferred tax assets	(6,261)	(6,261)
Total current assets	(1,442,445)	(1,055,859)
Non-current intercompany receivables	(433,678)	(407,304)
Investment in consolidated subsidiaries	(821,200)	(786,625)
Total assets	(2,697,323)	(2,249,788)
Current liabilities:
Current portion of capital lease obligations and other financing arrangements	(91,881)	(52,037)
Accrued payroll, accounts payable and accrued expenses	(12,728)
Intercompany payables	(1,331,575)	(997,561)
Total current liabilities	(1,436,184)	(1,049,598)
Deferred tax liability	(6,261)	(6,261)
Non-current intercompany liabilities	(433,678)	(407,304)
Total liabilities	(1,876,123)	(1,463,163)
Total inVentiv Health, Inc. stockholder's deficit	(821,200)	(786,625)
Total stockholder's deficit	(821,200)	(786,625)
Total liabilities and stockholder's deficit	(2,697,323)	(2,249,788)
Inventiv Health Inc [Member]
Current assets:
Cash and cash equivalents	65,509	19,643	7,183	33,176
Restricted cash	553	569
Intercompany receivables	488,420	375,025
Prepaid expenses and other current assets	8,541	5,301
Income tax receivable	85
Current deferred tax assets	259	259
Total current assets	563,367	400,797
Property and equipment, net	23,170	21,665
Deferred financing costs and other assets	51,690	64,484
Non-current intercompany receivables	403,917	368,325
Investment in consolidated subsidiaries	728,742	700,383
Total assets	1,770,886	1,555,654
Current liabilities:
Current portion of capital lease obligations and other financing arrangements		4,006
Accrued payroll, accounts payable and accrued expenses	80,456	62,179
Intercompany payables	809,634	562,297
Income taxes payable		222
Total current liabilities	890,090	628,704
Long-term debt, net of current portion	1,560,129	1,494,893
Deferred tax liability	333	333
Other non-current liabilities	20,989	37,441
Non-current intercompany liabilities		9,464
Total liabilities	2,471,541	2,170,835
Total inVentiv Health, Inc. stockholder's deficit	(700,655)	(615,181)
Total stockholder's deficit	(700,655)	(615,181)
Total liabilities and stockholder's deficit	1,770,886	1,555,654
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents		3,439	6,869	19,838
Accounts receivable, net of allowances for doubtful accounts	252,143	236,884
Unbilled services	196,521	138,100
Intercompany receivables	749,921	557,758
Prepaid expenses and other current assets	15,111	12,181
Income tax receivable	502	310
Current deferred tax assets	12,198	12,198
Total current assets	1,226,396	960,870
Property and equipment, net	90,853	82,857
Goodwill	889,281	889,281
Intangible assets, net	373,101	410,059
Deferred financing costs and other assets	12,624	14,331
Non-current intercompany receivables	29,625	38,847
Investment in consolidated subsidiaries	92,458	86,242
Total assets	2,714,338	2,482,487
Current liabilities:
Current portion of capital lease obligations and other financing arrangements	19,266	14,025
Accrued payroll, accounts payable and accrued expenses	190,314	162,937
Intercompany payables	501,879	404,413
Income taxes payable	75
Deferred revenue and client advances	174,532	150,709
Total current liabilities	886,066	732,084
Capital lease obligations, net of current portion	35,971	29,126
Long-term debt, net of current portion	576,339	576,339
Non-current income tax liability	5,543	5,360
Deferred tax liability	86,659	80,860
Other non-current liabilities	31,362	25,175
Non-current intercompany liabilities	404,050	368,457
Total liabilities	2,025,990	1,817,401
Total inVentiv Health, Inc. stockholder's deficit	688,348	665,086
Total stockholder's deficit	688,348	665,086
Total liabilities and stockholder's deficit	2,714,338	2,482,487
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	119,106	86,014	$ 93,982	$ 98,457
Restricted cash	1,419	1,148
Accounts receivable, net of allowances for doubtful accounts	55,905	65,963
Unbilled services	43,496	40,936
Intercompany receivables	93,234	64,778
Prepaid expenses and other current assets	19,987	20,743
Income tax receivable	930	1,053
Current deferred tax assets	1,586	1,316
Total current assets	335,663	281,951
Property and equipment, net	15,747	17,337
Goodwill	40,745	42,506
Intangible assets, net	6,685	7,765
Non-current deferred tax assets	3,824	3,944
Deferred financing costs and other assets	15,032	12,447
Non-current intercompany receivables	136	132
Total assets	417,832	366,082
Current liabilities:
Current portion of capital lease obligations and other financing arrangements	92,005	50,271
Accrued payroll, accounts payable and accrued expenses	60,866	61,497
Intercompany payables	20,062	30,851
Income taxes payable	2,725	987
Deferred revenue and client advances	54,953	48,421
Total current liabilities	230,611	192,027
Capital lease obligations, net of current portion	36	198
Non-current income tax liability	1,209	1,101
Deferred tax liability	3,844	2,300
Other non-current liabilities	18,230	18,140
Non-current intercompany liabilities	29,628	29,383
Total liabilities	283,558	243,149
Total inVentiv Health, Inc. stockholder's deficit	132,852	121,539
Noncontrolling interest	1,422	1,394
Total stockholder's deficit	134,274	122,933
Total liabilities and stockholder's deficit	$ 417,832	$ 366,082

Guarantor Financial Informati54

Guarantor Financial Information - Schedule of Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 521,410	$ 462,391	$ 1,461,804	$ 1,333,765
Reimbursed out-of-pocket expenses	87,931	62,460	238,331	182,815
Total revenues	609,341	524,851	1,700,135	1,516,580
Operating expenses:
Cost of revenues	336,753	302,389	946,320	869,359
Reimbursable out-of-pocket expenses	87,931	62,460	238,331	182,815
Selling, general and administrative expenses	140,738	140,853	424,375	425,189
Total operating expenses	565,422	505,702	1,609,026	1,477,363
Operating income (loss)	43,919	19,149	91,109	39,217
Loss on extinguishment of debt and refinancing costs		(10,062)		(10,062)
Interest income (expense), net	(57,294)	(54,988)	(170,877)	(160,672)
Other income	11,318		11,318
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	(2,057)	(45,901)	(68,450)	(131,517)
Income tax (provision) benefit	(4,395)	(2,281)	(11,661)	(9,979)
Income (loss) before income (loss) from equity investments	(6,452)	(48,182)	(80,111)	(141,496)
Income (loss) from equity investments	2	(34)	(1,289)	(270)
Income (loss) from continuing operations	(6,450)	(48,216)	(81,400)	(141,766)
Net income (loss) from discontinued operations, net of tax				(8,163)
Net income (loss)	(6,450)	(48,216)	(81,400)	(149,929)
Less: Net (income) loss attributable to the noncontrolling interest	(238)	(9)	(604)	(529)
Net income (loss) attributable to inVentiv Health, Inc.	(6,688)	(48,225)	(82,004)	(150,458)
Eliminations [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	(6,507)	(6,338)	(18,680)	(31,700)
Reimbursed out-of-pocket expenses	(104)	(30)	(242)	(271)
Total revenues	(6,611)	(6,368)	(18,922)	(31,971)
Operating expenses:
Cost of revenues	(5,896)	(5,929)	(17,043)	(30,027)
Reimbursable out-of-pocket expenses	(104)	(30)	(242)	(271)
Selling, general and administrative expenses	(611)	(409)	(1,637)	(1,673)
Total operating expenses	(6,611)	(6,368)	(18,922)	(31,971)
Income (loss) from equity investments	(38,384)	11,252	(48,273)	54,716
Income (loss) from continuing operations				54,716
Net income (loss)	(38,384)	11,252	(48,273)	54,716
Net income (loss) attributable to inVentiv Health, Inc.	(38,384)	11,252	(48,273)	54,716
Inventiv Health Inc [Member]
Operating expenses:
Selling, general and administrative expenses	22,866	13,892	59,444	31,693
Allocation of intercompany costs	(9,854)	(11,743)	(29,654)	(35,229)
Total operating expenses	13,012	2,149	29,790	(3,536)
Operating income (loss)	(13,012)	(2,149)	(29,790)	3,536
Loss on extinguishment of debt and refinancing costs		(3,570)		(3,570)
Interest income (expense), net	(44,994)	(42,273)	(134,399)	(122,959)
Other income	11,318		11,318
Intercompany interest income (expense)	12,342	10,767	35,265	31,265
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	(34,346)	(37,225)	(117,606)	(91,728)
Income tax (provision) benefit				(127)
Income (loss) before income (loss) from equity investments	(34,346)	(37,225)	(117,606)	(91,855)
Income (loss) from equity investments	27,658	(11,000)	35,602	(58,603)
Income (loss) from continuing operations				(150,458)
Net income (loss)	(6,688)	(48,225)	(82,004)	(150,458)
Net income (loss) attributable to inVentiv Health, Inc.	(6,688)	(48,225)	(82,004)	(150,458)
Guarantor Subsidiaries [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	408,448	346,452	1,138,337	989,307
Reimbursed out-of-pocket expenses	77,745	49,283	205,811	143,347
Total revenues	486,193	395,735	1,344,148	1,132,654
Operating expenses:
Cost of revenues	271,754	228,411	750,784	656,655
Reimbursable out-of-pocket expenses	77,745	49,283	205,811	143,347
Selling, general and administrative expenses	88,264	89,727	266,007	282,328
Allocation of intercompany costs	7,886	8,960	23,765	26,853
Total operating expenses	445,649	376,381	1,246,367	1,109,183
Operating income (loss)	40,544	19,354	97,781	23,471
Loss on extinguishment of debt and refinancing costs		(6,492)		(6,492)
Interest income (expense), net	(12,445)	(12,759)	(36,892)	(38,000)
Intercompany interest income (expense)	(12,025)	(10,157)	(34,551)	(29,324)
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	16,074	(10,054)	26,338	(50,345)
Income tax (provision) benefit	(1,488)	(893)	(6,113)	(6,584)
Income (loss) before income (loss) from equity investments	14,586	(10,947)	20,225	(56,929)
Income (loss) from equity investments	10,728	(286)	11,382	3,617
Income (loss) from continuing operations				(53,312)
Net income (loss) from discontinued operations, net of tax				(8,163)
Net income (loss)	25,314	(11,233)	31,607	(61,475)
Net income (loss) attributable to inVentiv Health, Inc.	25,314	(11,233)	31,607	(61,475)
Non-Guarantor Subsidiaries [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	119,469	122,277	342,147	376,158
Reimbursed out-of-pocket expenses	10,290	13,207	32,762	39,739
Total revenues	129,759	135,484	374,909	415,897
Operating expenses:
Cost of revenues	70,895	79,907	212,579	242,731
Reimbursable out-of-pocket expenses	10,290	13,207	32,762	39,739
Selling, general and administrative expenses	30,219	37,643	100,561	112,841
Allocation of intercompany costs	1,968	2,783	5,889	8,376
Total operating expenses	113,372	133,540	351,791	403,687
Operating income (loss)	16,387	1,944	23,118	12,210
Interest income (expense), net	145	44	414	287
Intercompany interest income (expense)	(317)	(610)	(714)	(1,941)
Income (loss) before income tax (provision) benefit and income (loss) from equity investments	16,215	1,378	22,818	10,556
Income tax (provision) benefit	(2,907)	(1,388)	(5,548)	(3,268)
Income (loss) before income (loss) from equity investments	13,308	(10)	17,270	7,288
Income (loss) from continuing operations				7,288
Net income (loss)	13,308	(10)	17,270	7,288
Less: Net (income) loss attributable to the noncontrolling interest	(238)	(9)	(604)	(529)
Net income (loss) attributable to inVentiv Health, Inc.	$ 13,070	$ (19)	$ 16,666	$ 6,759

Guarantor Financial Informati55

Guarantor Financial Information - Schedule of Consolidating Statement of Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Statement of Income Captions [Line Items]
Net income (loss)	$ (6,450)	$ (48,216)	$ (81,400)	$ (149,929)
Other comprehensive income (loss):
Foreign currency translation adjustment	(4,390)	(11,274)	(5,617)	(8,584)
Total other comprehensive income (loss)	(4,390)	(11,274)	(5,617)	(8,584)
Total comprehensive income (loss)	(10,840)	(59,490)	(87,017)	(158,513)
Less: Net (income) loss attributable to the noncontrolling interest	(238)	(9)	(604)	(529)
Total comprehensive income (loss) attributable to inVentiv Health, Inc.	(11,078)	(59,499)	(87,621)	(159,042)
Eliminations [Member]
Condensed Statement of Income Captions [Line Items]
Net income (loss)	(38,384)	11,252	(48,273)	54,716
Other comprehensive income (loss):
Foreign currency translation adjustment	8,532	17,335	10,269	14,841
Total other comprehensive income (loss)	8,532	17,335	10,269	14,841
Total comprehensive income (loss)	(29,852)	28,587	(38,004)	69,557
Total comprehensive income (loss) attributable to inVentiv Health, Inc.	(29,852)	28,587	(38,004)	69,557
Inventiv Health Inc [Member]
Condensed Statement of Income Captions [Line Items]
Net income (loss)	(6,688)	(48,225)	(82,004)	(150,458)
Other comprehensive income (loss):
Foreign currency translation adjustment	(4,390)	(11,274)	(5,617)	(8,584)
Total other comprehensive income (loss)	(4,390)	(11,274)	(5,617)	(8,584)
Total comprehensive income (loss)	(11,078)	(59,499)	(87,621)	(159,042)
Total comprehensive income (loss) attributable to inVentiv Health, Inc.	(11,078)	(59,499)	(87,621)	(159,042)
Guarantor Subsidiaries [Member]
Condensed Statement of Income Captions [Line Items]
Net income (loss)	25,314	(11,233)	31,607	(61,475)
Other comprehensive income (loss):
Foreign currency translation adjustment	(5,260)	(8,724)	(5,582)	(7,382)
Total other comprehensive income (loss)	(5,260)	(8,724)	(5,582)	(7,382)
Total comprehensive income (loss)	20,054	(19,957)	26,025	(68,857)
Total comprehensive income (loss) attributable to inVentiv Health, Inc.	20,054	(19,957)	26,025	(68,857)
Non-Guarantor Subsidiaries [Member]
Condensed Statement of Income Captions [Line Items]
Net income (loss)	13,308	(10)	17,270	7,288
Other comprehensive income (loss):
Foreign currency translation adjustment	(3,272)	(8,611)	(4,687)	(7,459)
Total other comprehensive income (loss)	(3,272)	(8,611)	(4,687)	(7,459)
Total comprehensive income (loss)	10,036	(8,621)	12,583	(171)
Less: Net (income) loss attributable to the noncontrolling interest	(238)	(9)	(604)	(529)
Total comprehensive income (loss) attributable to inVentiv Health, Inc.	$ 9,798	$ (8,630)	$ 11,979	$ (700)

Guarantor Financial Informati56

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net cash provided by (used in) continuing operations	$ 53,318	$ (78,846)
Net cash provided by (used in) discontinued operations		(7,435)
Net cash provided by (used in) operating activities	53,318	(86,281)
Cash flows from investing activities:
Purchases of property and equipment	(28,619)	(24,250)
Proceeds from sale of business	10,691
Proceeds from vehicle sales	6,413	3,785
Proceeds from life insurance distribution	1,800
Return of (disbursements for) investments	224	(2,625)
Other, net	4,983	3,206
Net cash provided by (used in) investing activities	(4,508)	(19,884)
Cash flows from financing activities:
Repayments on capital leases	(20,174)	(12,205)
Borrowings under line of credit	153,000	262,000
Repayments on line of credit	(153,000)	(262,000)
Payment on installment note related to acquisition	(1,750)	(1,500)
Proceeds from issuances of debt		50,000
Payments of debt issuance costs	(324)	(2,319)
Repayment of debt and other financing arrangements	(2,527)	(3,525)
Other, net	(929)	(430)
Net cash provided by (used in) financing activities	(25,704)	30,021
Effects of foreign currency exchange rate changes on cash	(159)	(5,291)
Net increase (decrease) in cash and cash equivalents	22,947	(81,435)
Cash and cash equivalents, beginning of period	57,059	116,227
Cash and cash equivalents, end of period	80,006	34,792
Eliminations [Member]
Cash flows from operating activities:
Net cash provided by (used in) operating activities	(12,728)
Cash flows from investing activities:
Intercompany transfers	(162,747)	(111,835)
Net cash provided by (used in) investing activities	(162,747)	(111,835)
Cash flows from financing activities:
Intercompany transfers	122,903	73,837
Net cash provided by (used in) financing activities	122,903	73,837
Net increase (decrease) in cash and cash equivalents	(52,572)	(37,998)
Cash and cash equivalents, beginning of period	(52,037)	(35,244)
Cash and cash equivalents, end of period	(104,609)	(73,242)
Inventiv Health Inc [Member]
Cash flows from operating activities:
Net cash provided by (used in) continuing operations		(143,327)
Net cash provided by (used in) operating activities	(113,073)	(143,327)
Cash flows from investing activities:
Purchases of property and equipment	(8,530)	(9,760)
Proceeds from sale of business	10,691
Proceeds from life insurance distribution	1,800
Return of (disbursements for) investments	224	(2,625)
Intercompany transfers	159,339	86,267
Other, net	17	(62)
Net cash provided by (used in) investing activities	163,541	73,820
Cash flows from financing activities:
Borrowings under line of credit	153,000	262,000
Repayments on line of credit	(153,000)	(262,000)
Payment on installment note related to acquisition	(1,750)	(1,500)
Proceeds from issuances of debt		50,000
Payments of debt issuance costs	(324)	(2,319)
Repayment of debt and other financing arrangements	(2,175)	(2,821)
Other, net	(353)	154
Net cash provided by (used in) financing activities	(4,602)	43,514
Net increase (decrease) in cash and cash equivalents	45,866	(25,993)
Cash and cash equivalents, beginning of period	19,643	33,176
Cash and cash equivalents, end of period	65,509	7,183
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash provided by (used in) continuing operations		60,391
Net cash provided by (used in) discontinued operations		(7,435)
Net cash provided by (used in) operating activities	141,330	52,956
Cash flows from investing activities:
Purchases of property and equipment	(15,292)	(10,115)
Proceeds from vehicle sales	6,413	3,785
Intercompany transfers	3,408	25,568
Other, net	5,271	3,268
Net cash provided by (used in) investing activities	(200)	22,506
Cash flows from financing activities:
Repayments on capital leases	(19,863)	(12,073)
Repayment of debt and other financing arrangements	(352)	(704)
Intercompany transfers	(124,354)	(75,654)
Net cash provided by (used in) financing activities	(144,569)	(88,431)
Net increase (decrease) in cash and cash equivalents	(3,439)	(12,969)
Cash and cash equivalents, beginning of period	3,439	19,838
Cash and cash equivalents, end of period		6,869
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash provided by (used in) continuing operations		4,090
Net cash provided by (used in) operating activities	37,789	4,090
Cash flows from investing activities:
Purchases of property and equipment	(4,797)	(4,375)
Other, net	(305)
Net cash provided by (used in) investing activities	(5,102)	(4,375)
Cash flows from financing activities:
Repayments on capital leases	(311)	(132)
Intercompany transfers	1,451	1,817
Other, net	(576)	(584)
Net cash provided by (used in) financing activities	564	1,101
Effects of foreign currency exchange rate changes on cash	(159)	(5,291)
Net increase (decrease) in cash and cash equivalents	33,092	(4,475)
Cash and cash equivalents, beginning of period	86,014	98,457
Cash and cash equivalents, end of period	$ 119,106	$ 93,982